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Ireland
In May 2017, the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) published 
the European drug report 2017: trends and 
developments summarising the latest trends across 
the 28 EU member states, Norway and Turkey.1 
The report highlights the findings a major school survey in 2016 
that showed that last-month cannabis use among European school 
students was around half the level reported in a similar study from 
the US. Cannabis use among school students in Europe appears to 
be stable while smoking and drinking is declining. The percentage of 
European students reporting last-month alcohol use was more than 
double (49%) that reported by their American peers (21%).2 
An estimated 8,440 people died from drug overdose, mainly 
related to heroin and other opioids, in 2015. This is the third year in 
a row that overdose deaths in Europe have increased. Methadone-
related deaths exceed heroin-related deaths in four European 
countries, including Ireland. Supervised drug consumption facilities 
are available in seven European countries and ten countries are 
running take-home naloxone programmes. Naloxone is an opioid 
overdose-reversal drug.
The newsletter of 




L to R: Alexis Goosdeel, Director 
EMCDDA, Commissioner Dimitris 
Avramopoulos, Laura d’Arrigo, 
Chair EMCDDA Management 
Board at the launch of the 
European Drug Report  
in Brussels
In brief
The Steering Committee appointed by the 
Minister with responsibility for the national 
drugs Strategy to provide guidance and 
advice in the development of the new 
strategy finished their deliberations in June. 
The members of the committee considered how the 
new strategy should address problem drug use and what 
structural arrangements were needed to support this task. 
The work of the Steering Committee was informed by a 
report from an international expert review group, a review 
of international evidence on responses to problem drug 
use, an overview of trends over a 10-year period, reports 
from focus groups dealing with the themes of education 
and prevention, the continuum of care, supply reduction 
and evidence and best practice, and a report on a public 
consultation process.
In 2016, Drugnet Ireland looked at a selection of drugs 
strategies from different countries and outlined the range 
of strategic approaches that are being taken to deal with 
the challenge of problem drug use. This is the international 
context in which Ireland’s new strategy is being developed.
Many recent national strategies have included illicit 
substances. Australia, New Zealand, Sweden and Spain cover 
alcohol in their strategies, while Cyprus and and the UK deal 
with the harmful use of alcohol in their strategic approach. 
The Czech Republic, Croatia, France and Germany 
include addictive behaviours, such as gambling, as well as 
substances in their strategies.
A further strategic development in recent years has been 
the setting of national drugs strategies within the framework 
of wider governmental objectives, such as societal wellbeing 
or economic development. The countries that illustrate this 
shift most clearly are New Zealand and Scotland. Another 
recent change in emphasis has been the prominence given 
to instrumental guiding principles over the more traditional 
strategic objectives of reducing supply and demand and 
minimising harm. These principles include long-term and 
comprehensive planning, realistic decision-making — using 
evidence and evaluation of effectiveness, rational funding 
and service quality guarantee, and social participation 
as a way of raising awareness in society at large. Several 
European strategies explicitly mention ‘European values’ 
such as human dignity, freedom, equality, solidarity, 
democracy and the rule of law.
In this issue of Drugnet Ireland, we look at the report of 
the expert review group who visited Ireland last year and 
undertook a high-level review of the current National 
Drugs Strategy, and reported to the Steering Committee 
on their findings and observations. The group’s terms of 
reference enabled it to provide an objective assessment of 
the current strategy and present options, based on analysis 
of international trends, that the Steering Committee could 
consider in the development of Ireland’s new strategy. This 
review, along with the other information resources prepared 
for the Steering Committee, comprise a rich source of 
knowledge that will continue to be used to inform policy and 
practice as the new strategy progresses.
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opioids (mainly heroin)
• There was an estimated 1.3 million high-risk opioid users 
in Europe in 2015.
• Of the 191,000 clients entering specialised treatment and 
reporting opioids as their primary drug in 2015, 29,000 
were first-time entrants. The numbers of new entrants to 
treatment had declined from 56,000 in 2007, when they 
accounted for 36% of all new clients, to 23,000 in 2013.
• In 2015, 17 European countries reported that more than 
10% of all opioid clients entering specialised services 
presented for problems primarily related to opioids 
other than heroin, including methadone, buprenorphine, 
fentanyl, codeine, morphine, tramadol and oxycodone. 
• Among first-time clients entering drug treatment in 
2015 with heroin as their primary drug, 29% reported 
injecting as their main route of administration, down 
from 43% in 2006.
• The EMCDDA estimates that at least 7,584 overdose 
deaths occurred in the EU in 2015, an increase from the 
6,800 figure recorded in 2014. The reported number 
of overdose deaths increased among older age groups 
between 2007 and 2015, while those among younger age 
groups decreased. 
• Viral hepatitis, particularly infection caused by the 
hepatitis C virus (HCV), is highly prevalent among 
injecting drug users across Europe, with 5 of the 13 
countries with national data reporting a prevalence 
rate in excess of 50% in 2014-15. Drug injection is a risk 
factor for other infectious diseases, including hepatitis B, 
tetanus and botulism.
• The quantity of heroin seized within the EU had been 
declining steadily between 2002 and 2013 when 5.6 
tonnes were seized. A total of 8.9 tonnes were seized in 
2014, but in 2015 some 4.8 tonnes were seized, a return 
to the levels registered in the early 2010s. The reversal 
in trends in 2015 was largely due to an increase in large 
seizures (above 100 kg ) in several countries.
Cocaine
• Cocaine is the most commonly used illicit stimulant drug 
in Europe. Its use is more prevalent in the south and 
west of Europe. It is estimated that about 2.3 million 
young adults aged 15 to 34 (1.9% of this age group) 
used cocaine in the last year. Only Ireland, Spain, the 
Netherlands and the United Kingdom (UK) reported last-
year prevalence of cocaine use among young adults of 
2.5% or more.
• The decreases in cocaine use reported since 2008 had 
not been observed in the most recent surveys; of the 
countries that have produced surveys since 2014, three 
reported higher estimates, 12 reported a stable trend 
and one reported lower estimates than in the previous 
comparable survey. 
• Overall, cocaine was cited as the primary drug by 63,000 
clients entering specialised drug treatment in 2015, 
with the UK accounting for almost three-quarters of all 
reported treatment entries for cocaine. After a period 
of decline, the overall number of cocaine first-time 
treatment entrants has been stable since 2012 and there 
were 28,000 first-time clients in 2015.
While the number of new substances being introduced to the 
drug market has declined, the overall number of substances 
now available continues to grow. In 2016, the EMCDDA 
monitored more than 620 new psychoactive substances 
(NPS), compared with around 300 monitored in 2013. The 
slower rate of detection of new substances may be due to a 
more restrictive legal environment in some member states 
and operations against NPS laboratories in China. 
At the launch of the report, Dimitris Avramopoulos,  
European Commissioner for Migration, Home Affairs and 
Citizenship, said:
The impact of the drugs problem continues to be a 
significant challenge for European societies. Over 
93 million Europeans have tried an illicit drug in 
their lives and overdose deaths continue to rise for 
the third year in a row. I am especially concerned 
that young people are exposed to many new and 
dangerous drugs. Already 25 highly potent synthetic 
opioids have been detected in Europe between 2009 
and 2016, of which only small volumes are needed 
to produce many thousands of doses, thus posing a 
growing health threat.
The situation described in the European drug report is 
presented below under a series of headings. The EMCDDA 
used the most recent data available to provide aggregate 
figures. While data on some indicators, such as treatment 
demand, are supplied annually, the years of the most recent 
prevalence data can vary. 
Cannabis
• The EMCDDA estimates that around 17.1 million (13.9%) 
of young Europeans (15–34 years) used cannabis in the 
last year, 10 million of whom (17.7% of this age group) are 
aged 15-24 years. 
• The most recent survey results show that countries 
continue to follow divergent paths in last-year cannabis 
use. Of the countries that have produced surveys since 
2014, nine reported higher estimates, six were stable 
and two reported lower estimates than in the previous 
comparable survey.
• Levels of lifetime cannabis use in 2014 among school-aged 
children was, on average, 18%, with the highest levels 
reported by the Czech Republic (37%) and France (31%).
• The number of first-time treatment entrants for cannabis 
as their main problem drug increased from 43,000 in 
2006 to 76,000 in 2015. It is estimated that around 1% of 
European adults are daily or almost daily cannabis users. 
• In 2015, 703,000 seizures of cannabis were reported in 
the European Union (EU) (416,000 of herbal cannabis, 
287,000 of cannabis resin). There were a further 21,000 
seizures of cannabis plants. The quantity of cannabis 
resin, transported in large quantities and over long 
distances, seized in the EU is much higher than that of 
herbal cannabis (537 tonnes vs 73 tonnes). 










   












17 • Synthetic cathinones are the second largest group of new 
drugs monitored by the EMCDDA. In total, 118 synthetic 
cathinones have been identified since 2005, with 14 
reported for the first time in 2016, a decrease from the 31 
reported in 2014. 
• The number of detections of new opioids and 
benzodiazepines rose markedly in 2016. Nine new opioids 
were detected for the first time in 2016. Over 60% of the 
600 seizures of new synthetic opioids reported in 2015 
were fentanyl derivatives. Over 300,000 tablets containing 
benzodiazepines, such as clonazolam, diclazepam, 
etizolam and flubromazolam were seized in 2015. This 
figure was almost twice the number reported in 2014.
• The EMCDDA estimates that 2.3 million young adults 
(15–34 years) used MDMA/ecstasy in the last year (1.8% 
of this age group), with national estimates ranging from 
0.3% to 6.6%. These figures suggest an increase in use 
following a number of years of decline.
• Around two-thirds of European countries (19) reported 
some level of use of new psychoactive substances 
among their populations of high-risk opioid and 
stimulant users. The injection of synthetic cathinones 
among these groups was reported, with the substance 
used often varying by country.
Accompanying the European drug report 2017 will be 
Perspectives on Drugs (PODs), online interactive articles 
providing insights into specific issues in the drugs field. A 
number of these PODs have been updated and are published 
today alongside the report. The themes covered are cannabis 
resin market, drug consumption rooms, preventing overdose 
deaths in Europe, synthetic cannabinoids in Europe, and 
wastewater-based epidemiology.
 1  European Monitoring Centre for Drugs and Drug Addiction 
(2017) European drug report 2017: trends and developments. 
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/27401/
2  For further information, visit  
http://www.emcdda.europa.eu/edr2017 
• In 2014, almost 7,400 clients entering treatment in 
Europe reported crack cocaine as their primary problem 
drug, with the UK accounting for more than half of these 
(4,800), and Spain, France and the Netherlands most of 
the remainder (1,900).
• In the UK, deaths involving cocaine increased from 169 
in 2013 to 320 in 2015. In Spain, where cocaine-related 
deaths have been stable for some years, the drug 
continued to be the second most-often cited drug in 
overdose deaths in 2014 (269 cases). 
• In 2015, around 88,000 seizures of cocaine, amounting to 
68.7 tonnes, were reported in the EU. The situation has 
remained relatively stable since 2007, although both the 
number of seizures and the quantity seized has increased 
between 2014 and 2015.
other stimulants and new  
psychoactive substances
• Data on new psychoactive substances are based on 
notifications by member states to the EU Early Warning 
System (EWS). In 2016, 66 new substances were reported 
for the first time (98 in 2015). By the end of 2016, the 
EMCDDA was monitoring more than 620 NPS, compared 
with around 300 monitored in 2013. 
• In 2015, almost 80,000 seizures of NPS were made 
across Europe, more than double the number reported 
in 2014. Together, synthetic cannabinoids and cathinones 
accounted for almost 60% of the total number of all 
seizures of NPS. 
• In 2015, synthetic cannabinoids accounted for just over 
24,000 seizures. This represents an increase of almost 
7,000 seizures compared to 2014 figures. Since 2008, 169 
synthetic cannabinoids have been detected in a range 
of different products — including 11 new cannabinoids 
reported in 2016, and these continue to be the largest 
group of new drugs monitored by the EMCDDA. 
european drug trends 2017 continued
L to R: HRB librarians, Mairea Nelson, 
Louise Farragher (conference organiser) 
and Mary Dunne at the ICML/EAHIL 
conference in Dublin Castle in June
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mechanism it established, and in respect to its content 
which allowed priorities to be identified and targeted’ (p. 
6). It helped ‘facilitate multiagency working, encouraged 
stakeholder buy-in, and helped galvanise political support 
for drug issues’ (p. 7). Over the course of the strategy, 
progress had been made on many of the priority areas. In 
particular, it had been successful in targeting resources and 
developing services for opiate users. 
However, the review also found that while delivery of 
the strategy got off to a good start, over time some 
of the positive changes delivered in the initial phases 
‘became less apparent’ (p. 6) and the ‘usefulness and 
appropriateness of the instrument declined’ (p. 8). Areas 
that became problematic included: ‘[meeting] changing 
needs, stakeholder participation, sustaining appropriate 
coordination mechanisms, and follow up and continuing 
relevance of actions’ (p. 6). Griffiths et al. argued that it 
was inevitable that changes would occur over the period 
of a drugs strategy and it was therefore important that the 
strategy would adapt to meet these changes. The review 
discussed a number of areas in which the NDS had lost its 
momentum over time, including: 
• The ‘strong role of community organisations’ in both 
strategy development and delivery was identified as  
one of the key features of the Irish context (p. 9).  
In the course of the review, they found that in some 
areas of the NDS the coordination between local, 
regional and the national level became less effective 
over time. Roles and responsibilities became less clear 
and lines of communications blurred. This impacted on 
progress in a number of ways. One of these was that 
it meant opportunities to identify and adopt effective 
interventions were sometimes missed: ‘The need for 
effective engagement with local communities, needs 
based service provision, and mechanisms to ensure  
the quality of services delivered across locations,  
came up repeatedly during discussion on the current 
strategy’ (p. 10). 
• The impact of the strategy appeared to vary across 
geographical areas – in particular the impact on local 
structures, services and practice. This was influenced by 
‘changes in the location of needs since the drafting of 
the last strategy; the difficulty of reconfiguring delivery 
structures in response to these changes; and practical 
and resource issues related to developing service models 
suitable for areas where the target population is more 
geographical dispersed’ (p. 9). 
• The policy and operational landscape changed a lot over 
the course of the strategy. New strategies and structures 
had been developed across related fields. This had 
brought about ‘some corresponding lack of clarity on 
the purpose and/or role of different structures or actors 
working in the area’ (p. 6).
• The commitment to research, monitoring and evidence-
based interventions in the NDS was seen as one of its 
strengths. However, momentum in this area had faded 
over time. It was seen as having faced some ‘problematic 
coordination and structural issues’ (p. 11), including 
inadequate resourcing, a lack of standardisation for 
data collection, and a lack of capacity to analyse data 
collected and use it to inform strategic decisions.
POLICY AND LEGISLATION 
Rapid expert review 
of Ireland’s National 
Drugs Strategy 
The Cabinet Committee on Social Policy and Public Service 
Reform in 2015 mandated the Department of Health to 
develop the new National Drugs Strategy (NDS) to follow 
on from that which ran from 2009 to 2016. Late in 2015, 
the then Minister of State with responsibility for the NDS, 
Aodhán Ó Ríordáin TD, established a Steering Committee to 
provide him with guidance and advice in the development 
of the new NDS covering the period 2017-2024. The work of 
this committee has been informed by a number of inputs, 
including a report from a group of international experts1 who 
undertook a high level review of the National Drug Strategy 
2009−2016.2,3 
The Report of the rapid expert review of the National 
Drugs Strategy 2009−2016 was completed in August 2016.4 
It aimed ‘to inform the development of the next National 
Drugs Strategy by providing a “helicopter view” of and 
capturing some key learning points from the experiences of 
the National Drugs Strategy 2009−2016’ (p. 1). The review 
highlights the complexities involved in developing a drugs 
strategy in a landscape that is always evolving and in which 
‘articulation between social, criminal, and health policy areas 
is vital’ (p. 31). The group’s terms of reference were:  
• To examine the progress and impact of the 2009−2016 
NDS in the context of the objectives, key performance 
indicators and actions set out in the strategy. 
• To identify deficits in the implementation of the strategy. 
• To summarise success factors or barriers to success. 
• To comment on Ireland’s evolution in tackling the drug 
problem in the light of international trends. 
• To identify key learning points arising from the strategy 
and to highlight areas to consider for development in the 
new NDS. 
The review was based on documentary evidence, meetings 
and site visits held during a week-long visit to Ireland 
in January 2016. The review team met with a range of 
stakeholders, including Government officials, statutory and 
voluntary sector service providers, community members, 
and service users. It is important to note that this was not an 
evaluation of the NDS. This article presents just some of the 
key findings from the review. 
National Drugs Strategy 2009−2016
The 2009−2016 NDS was described by Griffiths et al. as a 
‘well-crafted and comprehensive version of a contemporary 
EU drugs strategy’ (p. 2) of its time. Overall, those they 
consulted considered it to have been ‘a valuable instrument, 










   












17 • Ensure equality of access to provision according to 
need: They argued that this is a concept that should 
cut across the strategy. High-quality interventions, of 
proven effectiveness, need to be universally available, 
irrespective of the types of drugs being used, where the 
user lives, or which community the user belongs to.
• Identify and roll out good practice: In the course of 
the review, the authors were presented with numerous 
examples of good practice, but it appeared there 
were barriers to them being implemented nationally. 
They argued for ‘a clear mechanism for identifying 
good practice, supporting programme evaluation, 
and encouraging wider implementation where this is 
appropriate’ (p. 10). They suggested drawing on national 
and international practice and programmes to develop a 
suite of approved interventions that have been proven to 
work and from which partners could draw.
• Monitor, research and evaluate: These are considered ‘an 
essential element of any strategic response in this area’ (p. 
31). This would help ensure that the strategy is responsive 
to changing needs and will deliver on the goals. Following 
on from this, there needs to be mechanisms in place to 
facilitate the analysis of what is found and the provision 
of advice based on this evidence to relevant stakeholders. 
Stakeholders would therefore be able to spread good 
practice and identify problem areas.
• Clarity of structural functions for implementation and 
delivery: The strategy should have a clear focus on how 
it is to be implemented and delivered, including the 
organisational structure and roles and responsibilities 
of the various stakeholders. To facilitate the delivery of 
the strategy, they highlight the importance of leadership 
(ideally at a ministerial level with the support of a 
committee) to provide drive, direction/prioritisation and 
to ensure resources are made available. 
• Alcohol: The authors gave special mention to alcohol  
as a theme that recurred throughout the review –  
the high prevalence of problems associated with it,  
the ‘interactions’ (p. 6) between alcohol and other  
drug problems, and its place in the forthcoming  
strategy. While Griffiths et al. do not identify a specific 
model to follow, they note that what is important in  
areas like prevention and treatment, where a ‘cross-
substance approach is essential’ (p. 12), is that they  
are adequately supported.
Specific issues for new NDS
Section 4 of the review identified a long list of specific 
issues that the team considered important for inclusion 
in the new strategy. Replicating the full list is beyond the 
scope of this article. However, current issues in Ireland 
that reflect those in other EU states included: meeting the 
needs of an ageing cohort of opiate users; new psychoactive 
substances; concern about cannabis in its various forms, in 
particular high potency products; and, the negative impact 
of criminalising users, especially young cannabis users. Issues 
that appeared to be of particular relevance to Ireland were 
problematic prescription drug use, the spread of opiate use 
to rural areas, drug-related intimidation, and homelessness 
and housing insecurity.
As mentioned above, this report is not an evaluation of the 
NDS, rather it sets out to take lessons from its delivery to 
inform the new NDS. This article presents just some of its key 
findings with far more detail available in the full report.
Structure of the NDS
To take learning from the experience of the NDS, the review 
discussed the effects of three elements of the NDS structure:
 
• The topic areas of the five pillars were described as ‘well 
chosen’, as they contained all the main elements of a 
‘modern balanced drug strategy’ (p. 8). There were pros 
and cons to structuring the NDS around the pillars. By 
keeping similar areas together, it gave clarity to the main 
tenets of the strategy. Having a ‘point of focus’ (p. 7) 
encouraged joined up working in some areas. However, 
it also impeded cross-pillar coordination at times, in 
particular when resources were limited or reduced. Where 
issues cut across more than one pillar, they sometimes 
lacked ownership and failed to be addressed. However, the 
overall view was that the benefits of the pillar approach 
outweighed the costs of it. Griffiths et al. suggest that the 
new strategy could be designed in a way to maintain the 
clarity that comes from keeping similar areas together but 
also facilitates better cross-area working.
• Actions were embedded in the seven-year strategy. 
Doing so was found to have particular limitations. The 
actions could not be reactive to change in the drug 
situation over time, and this contributed to an overall 
perception of a decline in the NDS’s ‘relevance and 
momentum’ (p. 6) over its timeframe. 
• The NDS included a set of key performance indicators 
(KPIs). These were to be used to measure progress 
over time. Their appropriateness as measures for both 
changes over time and the strategic goals they were 
linked to was not always clear. Furthermore, the data 
needed to measure them were not always available and 
investment in monitoring the KPIs ‘appeared to decline’ 
(p. 6) over the course of the strategy. They therefore did 
not fulfil their intended role. The authors suggested that 
the objectives, actions and KPIs need to be more clearly 
linked together and better sequenced to ensure they  
are achievable.
New NDS
Based on their findings, the authors made a number of 
suggestions for the development of the new NDS. These 
included:
• Separate the actions from the strategy: Given the 
relatively long period of time covered by Ireland’s  
current and forthcoming strategies, Griffiths et al.  
argued strongly for separating the strategy from the 
actions. The strategy document could lay out the vision, 
objectives and structure for the seven years; and a 
separate time-bound (e.g. three years) action plan could 
support the strategy. This approach would allow for an 
opportunity to reflect on progress and changes in the 
landscape at a midpoint in the strategy’s timeframe and 
to make appropriate changes to the action plan.
• Synergise with other strategies: To minimise 
duplication, the waste of scarce resources and 
to maximise the impact of strategies, the authors 
emphasised the importance of having clear ‘synergy and 
complementarity’ (p. 31) between the new NDS and other 
related strategies. This would include strategies dealing 
with other substances (in particular alcohol), the needs 
of specific populations, areas, or social issues where drug 
use is an issue. 
rapid expert review continued
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The attitude of staff members is key; they need to be able 
to deal with the paradox of being healthcare professionals 
(in some cases), while also supervising injecting, which is 
an ‘inherently dangerous activity’ (p. 14), as well as always 
treating service users humanely.
Place
the building: It was suggested that the building should not be 
overly clinical. Instead, it should be a safe place for people 
suited to the development of therapeutic relationships. For 
accessibility, it should be in the city centre. A mobile facility 
could be considered, as it could follow the flow of the target 
population.
Engaging the community: The location of the facility has 
attracted a lot of interest in the broader community and 
it was expected that NIMBYism would be an issue. First, it 
was suggested that the supervised injecting facility would 
need to follow the practice of existing drug services in 
Dublin of engaging proactively with the community. Based 
on international experience, this would be an important 
element of the ongoing management of the facility. 
Second, communities elsewhere were reported to have 
been ultimately welcoming of these facilities despite initial 
opposition. They had a positive effect on an area, and the 
need to collect good baseline data to be able to evidence 
any such changes was noted.
Integration with other services: Supervised injecting 
facilities need to be embedded in the wider service 
landscape. First, there is a need to offer users access to 
other related services. This would require providers to 
identify and define pathways through the service and on to 
other services. Second, the provision of suitable ancillary 
services at the facility can be important, for example, access 
to food and showers.
Policing
Impact on drug markets and crime levels: As these facilities 
are not a criminal justice intervention, it was noted that they 
should not be expected to impact significantly on crime, 
either positively or negatively. The impacts will be in terms 
of the service user’s health and the public amenity. However, 
international examples show that these facilities are not 
associated with increases in crime. Similarly, they do not 
affect any change in the drug market.
Role of policing: There was much discussion about the 
complexities involved in the policing of the centre and a 
number of key points were identified. First was that the role 
of law enforcement agencies should not be underestimated in 
the successful delivery of the service. Establishing a positive 
and transparent relationship between police and the facility’s 
management was identified as crucial. 
Dublin Drug  
Policy Summit
The Dublin Drug Policy Summit was held on 20 January 2017. 
It was organised by the Ana Liffey Drug Project and attended 
by national and international experts on drug policy, including 
policy-makers, practitioners, and academics. Among the 
delegates were Minister of State for Communities and the 
National Drugs Strategy Catherine Byrne TD and Ruth Dreifuss, 
chair of the Global Commission on Drug Policy (GCDP).1 The 
summit focused on two issues: supervised injecting facilities 
and the decriminalisation of possession of drugs for personal 
use. This article is based on the published proceedings  
of the event, which present a thematic analysis of the  
issues discussed.2,3
Supervised injecting facilities
It is Irish Government policy to introduce a supervised 
injecting facility.4 The summit focused on discussing how 
best to operationalise the facility. The key points discussed 
were grouped under the broad themes of people, place,  
and policing.
People
Access criteria: There was general agreement among 
participants that any access criteria should be as broad as 
possible and that any related legislation should not extend 
to defining which groups could access the service. The two 
groups noted in particular were pregnant women and those 
aged under 18. However, it was agreed that access should 
only be given to people who are already injecting drug users. 
Specialised protocols could be put in place for particular 
groups, and practitioners would have the flexibility to make 
decisions on a case-by-case basis to best meet the service 
user’s needs.
An appealing service for potential service users: Having  
a service that appeals to users was considered critical.  
A number of themes were raised on this issue. First, there 
was both curiosity and apprehension among potential service 
users about what the service would be like and how it would 
work. Second, a good atmosphere and person-centred 
approach that builds positive relationships between staff and 
service users is what would truly make the service appealing. 
Third, the service needs to be accessible, and the importance 
of its proximity to where people buy their drugs was noted. 
While NIMBYism – Not in My Back Yard – may present 
challenges, evidence from other jurisdictions did not show a 
‘honeypot effect’ for supervised injecting facilities, i.e. they 
have not drawn in more dealers and users to an area. Finally, 
there were issues relating to the staffing of the facility. 
2 Department of Community, Rural and Gaeltacht Affairs (2009) 
National Drugs Strategy (interim) 2009−2016. Dublin: Department 
of Community, Rural and Gaeltacht Affairs. http://www.
drugsandalcohol.ie/12388/
3 Throughout this article, the National Drugs Strategy 2009−2016 will 
be referred to as the NDS. The National Drug Strategy 2017−2024 
will be referred to as the ‘new NDS’. 
4 Griffiths P, Strang J and Singleton N (2016) Report of the rapid 
expert review of the National Drugs Strategy 2009−2016. Dublin: 
Department of Health. http://www.drugsandalcohol.ie/27289/
Lucy Dillon
1 The expert review group included: Paul Griffiths, scientific 
director of the European Monitoring Centre on Drugs and Drug 
Addiction (EMCDDA), who chaired the group; Nicola Singleton, 
scientific analyst with the EMCDDA; and Professor John Strang, 
director of the National Addiction Centre, King’s College London.










   













Some of the discussion focused on what would be the most 
appropriate responses if someone were found in possession 
of drugs where it had been decriminalised. First, it was noted 
that decriminalisation does not mean the absence of any 
consequences for being found in possession of a controlled 
substance. Instead, these could take the form of a civil 
rather than a criminal sanction. Portugal’s experience was 
highlighted, with a focus on the benefits of having sanctions 
for possession that do not come with a criminal record, 
stigma or the expending of a large amount of resources. 
There was also a call for research on what would be the most 
appropriate responses in the Irish context. 
threshold limits
Threshold limits were also discussed, i.e. the amount of drugs 
that a person could possess before they were considered 
to be in possession for supply. While it was recognised that 
there was a need for thresholds to be established, it was also 
suggested that they should be carefully selected and should 
not be rigid. Instead, there should be flexibility to allow for 
the needs of the individual to be considered. By doing so, the 
courts could refer to the health authorities and vice versa.
Lucy Dillon 
1 The Global Commission on Drug Policy is ‘an international 
reference regarding the impacts of the current drug control 
strategy, proposing policy recommendations that protect  
human rights, scale-up harm reduction and promote 
development’. It is made up of 23 political leaders and 
leading thinkers from across the political spectrum. For more 
information, visit http://www.globalcommissionondrugs.org/ 
2 Ana Liffey Drug Project (2017) Dublin Drug Policy Summit. Dublin: 
Ana Liffey Drug Project. http://www.drugsandalcohol.ie/27186/ 
3 To facilitate a more open discussion, the summit followed the 
Chatham House Rule, whereby any reported views or comments 
from the session are not attributed to any particular individual 
or organisation. It is not suggested that all delegates agreed 
with or supported the statements reported in the proceedings 
document.
4 The Misuse of Drugs Act (Supervised Injecting Facilities) Bill 2017 
was published in February 2017.
Second were the complexities involved in the approach 
taken to the policing of service users. Experiences in other 
jurisdictions highlighted these in terms of decision-making 
on whether to stop and search people in the vicinity of these 
facilities, for example. Overall, it was noted that Irish police 
are ‘aware of the complexities of policing in the context of 
social and health issues and take a very pragmatic approach 
to dealing with people on the street every day’ (p. 19). While 
there was no clear answer as to what was the best approach, 
there was a clear call for discretion on the part of the police 
and for it to be applied consistently. This would be facilitated 
by legislative clarity. 
Decriminalisation
The decriminalisation of the possession of small amounts 
of drugs for personal use is not Government policy but an 
issue of growing debate. The discussion at the summit in 
this regard fell into three broad themes: general discussion, 
responses, and threshold limits.
General discussion
A number of key points were made during the general 
discussion on decriminalisation. First, it was important not 
to overstate its benefits – it was not a panacea and it alone 
would have little or no impact on levels of drug use. Where 
changes in the law have led to better outcomes for users 
(e.g. in Portugal), this was likely related to a broader shift in 
policy and investment in services, rather than a change in 
the law as such. Second, criminalisation causes harms. For 
example, it might mean users are less likely to access services, 
and labelling someone as a criminal can have a sustained 
negative effect on their life and opportunities. Third, the 
language used around the debate requires consideration; 
‘decriminalisation needs to be framed as a health and social 
issue rather than a criminal one’ (p. 21). Fourth, while some 
stakeholders were convinced about decriminalisation, others 
were not and concerns remained. These included concerns 
about the message it might send to (particularly young) people 
about drug use, and the new challenges it might present for 
law enforcement agencies. Finally, the importance of balance 
in drug policy generally was noted – ‘going too far either 
way on a restrictive/permissive spectrum is likely to result 
in significant harms and be unhelpful as a policy approach 
attempting to minimise harm’ (p. 21). 
Minister of State for Communities and 
the National Drugs Strategy Catherine 
Byrne TD with Tony Duffin, Ana Liffey Drug 
Project, at the Dublin Drug Policy Summit. 
(See report p. 7)
dublin drug Policy Summit continued
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and the patient population. Given the variation in what was 
explored in the studies, the team found it challenging to draw 
conclusions regarding the effectiveness of treatment.
Despite these limitations, the team found three medical 
conditions for which there was ‘some scientific evidence to 
support the use of cannabis or cannabinoids as a medical 
treatment in patients who have failed available treatments’ 
(p. 16). These were: 
• Spasticity associated with multiple sclerosis
• Intractable nausea and vomiting associated with 
chemotherapy
• Severe, refractory (treatment-resistant) epilepsy
However, there was insufficient evidence to support their use 
for other conditions, including chronic pain.
Access programmes
At the core of the review’s findings is HPRA’s 
acknowledgement that the Government may decide to 
make cannabis more readily available on a medicinal basis: 
‘The decision to permit access to cannabis for medical 
use is a societal and policy decision due to the paucity of 
scientific research, the recreational use of the product and 
the strong public and patient demand’ (p. 1). Any products 
or preparations extracted from the cannabis plant that are 
psychotogenic are currently controlled under the Misuse 
of Drugs legislation and their medical use is therefore not 
permitted.7 However, if the Minister for Health considers it 
to be in the public interest, a specific licence can be granted 
which allows a doctor to prescribe products containing THC. 
Any application for a licence must be accompanied by an 
endorsement from a medical consultant who is responsible 
for the care of the individual applicant. 
The authors argued that if cannabis were to be made more 
readily available for medical use in Ireland, then it should 
only be permitted under a controlled access programme 
for the treatment of patients with a selection of medical 
conditions. Any programme should be part of a ‘structured 
process of formal on-going clinical evaluation in a limited 
number of clearly defined medical conditions’ (p. 6). They 
advised that the programme be run for an initial period of 
5 years and be limited to the medical conditions outlined 
above. The programme should have the following features:
• Patients treated with cannabis should be under the 
care of a medical consultant who has expertise in the 
condition being treated. He/she would be responsible for 
the ongoing monitoring of the patient.
• There should be a central register for patients, doctors 
and pharmacists involved in the programme, with data 
collected on the use of cannabis by these patients.
• Authorised cannabis-based medicines should be the 
products considered first. If unsuitable, then cannabis 
products from other countries that have been subject to 
quality control requirements could be used.
• Patients should be educated about the correct use of 
any cannabis product provided, the benefits and risks 
involved, how to report any side-effects, and the care 
and safe disposal of cannabis products.
• Doctors and pharmacists should be supported in their 
prescribing and dispensing of the products (p. 6).
Cannabis for  
medical use: a 
scientific review
Cannabis for medical use: a scientific review1 was launched 
by Minister for Health Simon Harris TD on 10 February 2017. 
He described the review as a ‘milestone’ in the development 
of policy on medicinal cannabis in Ireland.2 The review was 
carried out by the Health Products Regulatory Authority 
(HPRA) in response to a request from the Minister in 
November 2016 for expert scientific advice on the use of 
cannabis for medical purposes. 
HPRA defined the medical use of cannabis3 as ‘a situation 
where a doctor prescribes or recommends the use of 
cannabis for treatment of a medical condition in a patient 
under his/her care’ (p. 9). It convened a group of clinical 
experts and patient representatives to assist them in 
carrying out the work. They did not undertake a systematic 
review of the data on cannabis for medical use. Instead, they 
reviewed a selection of what they considered to be the ‘main 
scientific reviews and relevant publications’ (p. 2).4 They also 
carried out a survey of HPRA’s global regulatory counterparts 
to explore the situation in other jurisdictions and their 
policies on access to cannabis for medical use.5 
The review covered four main themes: 
• The cannabis products available
• The regulatory regimes in countries where cannabis was 
allowed for medical purposes 
• The research on new indications and evidence of efficacy 
of cannabis for various medical conditions
• The current legal situation in Ireland and legislative 
changes required for cannabis to be made available for 
medical purposes here
This article focuses on elements of the last two themes.
Evidence of effectiveness
Overall, the team found an absence of scientific data 
demonstrating the effectiveness and safety of cannabis 
products (p. 1). They also found that most cannabis products 
available through international access programmes did not 
meet ‘pharmaceutical quality requirements’ (p. 1). As the 
regulator of medicines and other health products in Ireland, 
HPRA’s role is to ensure that any medicines available on the 
Irish market are ‘safe, effective and of an appropriate quality 
based on clinical and scientific data’ (p. 7). The authors found 
insufficient evidence to allow for cannabis products to be 
authorised as medicinal products (medicines) under this 
regulatory requirement. 
There were a number of complexities involved when 
examining the evidence base. For example, ‘a major 
limitation’ (p. 13) was the variation in the formulations of 
cannabis that had been studied, particularly in relation 
to the tetrahydrocannabinol (THC) and cannabidiol (CBD) 
ratio.6 Another was the variety of medical conditions under 
examination. The potential benefits and risks of cannabis 










   












17 4 The main documents used were: Barnes MP and Barnes JC (2016) 
Cannabis: the evidence for medical use. London: All-Party 
Parliamentary Group for Drug Policy Reform; Whiting PF, Wolff RF, 
Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, 
Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M and Kleijnen 
J (2015) Cannabinoids for medical use: a systematic review and 
meta-analysis. JAMA, 313(24): 2456–73; Hill KP (2015) Medical 
marijuana for treatment of chronic pain and other medical and 
psychiatric problems: a clinical review. JAMA, 313(24): 2474–83; 
National Academies of Sciences, Engineering and Medicine 
(2017) The health effects of cannabis and cannabinoids: the 
current state of evidence and recommendations for research. 
Washington DC: National Academies Press.
5 Forty countries were contacted and responses received from 28 
EU member states and seven non-EU states. 
6 The cannabis plant is reported to contain more than 100 plant 
cannabinoids; those thought to be the most important in terms 
of their clinical effects are tetrahydrocannabinol (THC) and 
cannabidiol (CBD). THC is the main psychotogenic component of 
cannabis. 
7 One cannabis-based medicine (Sativex®) has been authorised by 
HPRA for use with adult patients with moderate to severe spasticity 
due to multiple sclerosis (MS). Two other medicines based on the 
structure of THC were reported to be listed under Schedule 2 of 
the Regulations: nabilone and dronabinol. As CBD does not have 
any psychotogenic effects, products containing it alone do not fall 
under the Misuse of Drugs legislation and its restrictions.
8 Department of Health (2017) Minister Harris announces ‘pivotal 
step’ on medicinal cannabis access programme: prescribers, 
patients and pharmacists to draw up guidance for the safe use of 
cannabis-based treatments for qualifying patients. Available online 
at http://www.drugsandalcohol.ie/27104/ 
Ministerial response to the review
Following the publication of the report, the Minister for 
Health gave a commitment to establish a ‘compassionate 
access programme for cannabis-based treatments’.2 
His decision was based on the advice of HPRA and the 
programme will therefore only be accessible to people with 
one of the three medical conditions outlined above and will 
require the support of a medical consultant. In addition, the 
Department of Health has established an Expert Reference 
Group responsible for developing operational guidelines to 
facilitate the prescription and supply of medicinal cannabis 
to qualifying patients.8
Lucy Dillon
1 Health Products Regulatory Authority (2017) Cannabis for 
medical use: a scientific review. Dublin: Department of Health. 
http://www.drugsandalcohol.ie/26784/
2 Department of Health (2017) Minister Harris publishes  
‘milestone’ report on cannabis for medical use. Available online 
at http://health.gov.ie/blog/press-release/minister-harris-
publishes-milestone-report-on-cannabis-for-medical-use/ 
3 For the purpose of the report and this article, ‘references to 
cannabis include cannabis resin and other derivatives from the 
plant such as oils and other processed plant parts’ (p. 8).
respectively. In 2015, the national mean THC potency in 
cannabis resin ranged from 4% to 28%, while national mean 
THC potency in cannabis herb ranged from 3% to 22%.1 
obligations by countries to control cannabis
In accordance with international treaties, national drug 
laws are required to control the whole plant. However, in 
some EU member states, allowances are made for plants 
grown for fibre that have low THC content (<0.2%). National 
control is not required for cannabis seeds. By law cannabis 
or cannabis-based products may be used for medicinal 
purposes in EU member states, for example, THC in capsules, 
cannabis extract (e.g. Sativex®, a mouth spray used to treat 
multiple sclerosis), and dried cannabis flowers for vaporising 
or making tea. No EU member state allows cannabis to be 
smoked for medicinal purposes.
The control of cannabis and other drugs comes under 
United Nations conventions and stipulates that all controlled 
drugs must be restricted to medicinal or scientific 
purposes.3 Any unlawful behaviour (e.g. possession, 
acquisition, distribution or offering for sale, etc.) must 
be penalised, with serious offences being punished by 
withdrawal of freedom. With regard to cannabis use, the EU 
provides no ‘harmonised’ law to control cannabis usage (p. 
9);1 the responsibility for responding to drug use offences 
is placed solely with EU member states. However, EU law 
does exist for crimes related to the trafficking of cannabis.4 
With the aim of having a common approach to tackling 
drug trafficking throughout the EU, minimum provisions 
have been outlined for basic offences and penalties since 
2004 (p. 1).4 Possession for personal consumption was not 
included in these provisions.
Cannabis legislation  
in Europe:  
an overview
A recent study by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) carried out an overview 
of cannabis legislation in Europe focusing primarily on 
‘recreational’ use.1 In Europe, cannabis is the most commonly 
talked-about drug referred to in drug law offences reports 
(57%), and the most frequently used illicit drug in young 
adults (aged 15–34 years).2 Debates on the prohibition and 
permittance of cannabis use and supply are ongoing. This 
study aimed to provide answers to commonly asked questions 
that arise when cannabis legislation is being discussed. 
What is cannabis? 
Cannabis is defined as ‘any plant of the genus Cannabis’, 
which includes Cannabis indica, Cannabis sativa and any 
other species that is created in the future (p. 24).3 In most 
European Union (EU) countries, legal control occurs if the 
plant is able to produce a usable psychoactive substance 
called delta-9-tetrahydrocannabinol (THC). A higher 
concentration of THC (≤20%) is found in female flowers 
and resin-producing trichomes (plant hairs). Recreational 
cannabis is sold as herbal cannabis (i.e. resin-coated 
flowers) or cannabis resin (i.e. resin extracted and sold 
on its own). Between 2006 and 2015, mean potency of 
European samples of resin and herb rose by 90% and 80%, 
Cannabis for medical use continued
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The route taken by most member states to penalise cannabis 
use is via decriminalisation or depenalisation of offences 
by using non-criminal punishments or closing the case as 
minor. However, some member states use alternatives to 
punishment, for example, diverting offenders to rehabilitative 
or treatment services instead.
Future of cannabis legislation
In the previous two decades, the aim of legislation has been 
to decrease or remove prison penalties for minor cannabis 
possession offences. Primarily, legislative changes were 
applied to the level of penalty to ensure that the sentences 
were consistent, their severity corresponded with the health 
risks associated with different drugs, and to ensure that 
rehabilitation/treatment was given precedence ahead of 
punishment. No EU member state has removed all penalties 
nor have they made the supply of cannabis legal. More 
recently, decriminalisation or legalisation of recreational 
cannabis use is being debated among a number of EU member 
states. Although not discussed in this study, medicinal and 
industrial use of cannabis is also being debated.
Conclusion
This study provided an overview of legislative approaches 
to cannabis across EU member states. There is no 
common approach to targeting cannabis offences. In fact, 
considerable disparities were illustrated in how countries 
discern laws and penalties for cannabis sale or use. For 
legislative purposes, EU member states either treat all drugs 
the same, or view cannabis offences as less serious, or in 
some cases harsher penalties are applied. In the previous 
two decades, nearly 50% of EU member states altered 
legislation that targeted cannabis use. The impact on 
cannabis use is unclear, as no rigorous scientific evaluations 
were carried out to determine the effectiveness of the 
legislative changes. To date, cannabis policy is a topic of 
ongoing debate throughout EU member states and its 
development is being monitored by the EMCDDA.
Ciara H Guiney
1 European Monitoring Centre for Drugs and Drug Addiction  
(2017) Cannabis legislation in Europe: an overview.  
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/27071/
2 European Monitoring Centre for Drugs and Drug Addiction 
(2016) European drug report 2016: trends and developments. 
Luxembourg: Publications Office of the European Union.  
http://www.drugsandalcohol.ie/25579/ 
3 United Nations Office on Drugs and Crime (2013)  
The international drug control conventions. Vienna:  




4 Council of the European Union (2004) Council framework decision 
2004/757/JHA. Official Journal of the European Union, 11 Nov 
2004, L 335/8. Available online at https://db.eurocrim.org/db/en/
doc/247.pdf 
Laws and associated guidelines
Within EU member states, penalties applied to cannabis 
offences can be grouped in two ways. In some member 
states (e.g. Italy, UK and Portugal), cannabis is not treated 
like other drugs in that the level of penalty applied is linked 
to the level of harm caused. In this instance, penalties 
obtained for cannabis-related offences are less severe than 
those provided for other drugs, whereas in other member 
states, the same penalties, which tend to be more severe, 
are applied to all drugs. Where cannabis use is viewed as a 
minor offence, penalties are lower than that for other drugs 
(e.g. Ireland, Belgium and Luxembourg).
A positive drug test for drug use is not viewed as an offence 
under UN conventions; however, in some member states 
drug use is considered a serious offence and can result in 
police arrest (e.g. France, Norway and Cyprus). Nonetheless, 
how the law is enforced differs between countries; for 
instance, it can be used to enforce public order or to 
apprehend drug users, or can act as a road safety policy, for 
example, in tests for drug-related driving.
The penalty for possession of cannabis for personal use 
varies across the EU. The probability of being imprisoned 
for ‘small amounts’ has been declining since 2000 (p. 13). 
However, the definition of a small amount varies in EU 
member states; for example, in Belgium, imprisonment can 
occur for being in possession of small amounts of cannabis, 
yet police have been advised to record non-problematic 
cases locally instead of centrally. While in other EU member 
states (e.g. Denmark, France and UK), police and prosecutors 
are allowed to apply either a non-custodial penalty or 
dismiss the case.
Penalties for selling or trafficking cannabis vary substantially 
among EU member states, which makes comparison 
problematic between countries. For example, where 
cannabis supply is viewed as minor, in countries such as 
Denmark and Spain, maximum penalties can range from two 
to three years where as in Ireland and Cyprus the maximum 
penalty is life imprisonment. Other factors can also influence 
the outcome, such as whether the offender was involved 
with organised crime or gangs, the motive for the offence, or 
which court the offender was tried in. 
Driving under the influence of cannabis is considered illegal 
across all EU member states; however, how laws are phrased 
or interpreted varies considerably. 
Cannabis offenders in practice
An examination of legislation in EU member states does 
not provide an insight into how it is applied. This is the 
responsibility of law enforcement agencies, which may or 
may not be authorised to enforce legislation or may have 
to adhere to local or national directives that lay down how 
different offences should be responded to. Punishments for 
cannabis use provided by EU member states include fines, 
warnings, and community work orders, and in some cases 
suspended prison sentences. More often than not, the type 
of drug implicated has not been identified. 











   












17 The need for the outcome document to produce ‘concrete, 
operational results if it is ultimately to be deemed a success’ 
was noted.4 Among the challenges identified by the other 
UN entities in attendance were how different the situation 
currently exists in some states, when compared to what 
the outcome document required. For example, some of the 
OHCHR’s key points were:
• The right to life continues to be challenged in some 
states, in particular through extrajudicial executions of 
drug users and traffickers.
• Those suspected of drug-related offences are often 
detained unlawfully or confined to compulsory detention 
or treatment. 
• There has been a long history of inaction on the right 
to health of people in terms of their access to essential 
medicines, such as opioids for the relief of pain and for 
substitution therapy.
The UNDP5 highlighted how challenging many stakeholders 
found it to deliver a more human rights approach to drug 
control policy. They remarked that there is little clear, 
comprehensive assessment of how to effectively deliver it 
in practice. To fill this gap, they are working in collaboration 
with a number of partners to develop international guidelines 
on human rights and drug control.
In conclusion
Overall, the session was seen by commentators as indicating 
important progress by continuing the move more towards a 
health and human rights led approach to drug use reflected 
in the UNGASS document. For example, a HIV/AIDS-related 
resolution was passed that calls for member states to 
increase their funding for harm reduction activities for 
people who inject drugs.6 UNODC Chief Yury Fedotov closed 
the event with a focus on people’s health and welfare: 
Together we have made a commitment under the 
international drug control conventions to the health 
and welfare of people and communities everywhere 
– an enduring promise to millions of children, 
women and men that we must uphold.7
Lucy Dillon
1 United Nations Office on Drug and Crime (2016) Outcome 
document of the 2016 United Nations General Assembly Special 
Session on the world drug problem. Vienna: United Nations 
Office on Drug and Crime. Retrieved 11 April 2017 from:  
http://www.unodc.org/documents/postungass2016//outcome/
V1603301-E.pdf
2 Dillon L (2017) Responses to UNGASS 2016. Drugnet Ireland, 60: 
8–9. http://www.drugsandalcohol.ie/26701/
3 United Nations Economic and Social Council (2017) Remarks 
by H.E. Ambassador Pedro Moitinho de Almeida, CND 
Facilitator for post-UNGASS Matters: Second round of thematic 
discussions on UNGASS follow-up (January 2017). New York: 
United Nations Economic and Social Council. Retrieved  




The Commission on Narcotic Drugs (CND) is the governing 
body of the United Nations Office on Drugs and Crime 
(UNODC). Essentially, it is the central drug policy-making 
body of the United Nations. Membership is made up of 
representatives from 53 UN member states, allowing for 
a spread of geographical representation. Ireland is not 
currently a member. The CND led preparations for the United 
Nations General Assembly Special Session (UNGASS) on the 
world drug problem held in 2016 and led negotiations on the 
associated outcome document.1 While that document was 
heavily criticised by some stakeholders, it was also seen as 
indicating a more progressive direction in terms of putting 
health, human rights, and development more at the core of 
drug policy.2
Implementing the UNGASS document
The CND is responsible for leading on the implementation 
of the recommendations of the document. Since UNGASS, 
they have appointed a ‘facilitator for post-UNGASS matters’ 
and have held a variety of meetings to progress the 
recommendations. They held two intersessional meetings 
to discuss each of the seven thematic areas covered in 
the UNGASS document. Member states, UN entities and 
specialised agencies, international and regional organisations 
and civil society (including non-governmental organisations) 
were all in attendance. The first meeting provided 
participants with an opportunity to share experiences across 
the themes, discuss lessons learnt, and report on ‘concrete 
activities’3 (p. 1) that had been undertaken to implement the 
UNGASS operational recommendations. The second meeting 
took a more forward-looking approach, focusing on what 
the CND could do to operationalise the recommendations. A 
recurring theme throughout the meetings was the need for 
the CND and UNODC to collaborate closely with all relevant 
UN entities and other international organisations and civil 
society to deliver on this work.3 
60th Session of CND
The CND’s 60th Session was held in Vienna (13–17 March 
2017) and provided a valuable opportunity to demonstrate 
improved collaboration. As well as the core plenary sessions, 
around 100 side events and numerous exhibitions were 
held. Approximately 1500 people attended the session, 
representing the same broad scope of stakeholders as 
the earlier thematic meetings. Among the main issues 
discussed was the implementation of the UNGASS outcome 
document. At a plenary session that dealt specifically with 
the follow-up to UNGASS, statements were made by member 
states, a number of other UN entities and civil society. The 
United Nations Development Programme (UNDP), Office of 
the United Nations High Commissioner for Human Rights 
(OHCHR), UNAIDS and the World Health Organization (WHO) 
all made statements welcoming the UNGASS document 
and its progress towards a more health and human rights 
approach to drug policy. The closer links it established 
with the UN’s Sustainable Development Goals were also 
welcomed.4,5 
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6 Fordham A (2017) Drugs at the UN: the needle inches forward. 
London: International Drug Policy Consortium. Retrieved 11 April 
2017 from: http://idpc.net/blog/2017/04/drugs-at-the-un-the-
needle-inches-forward
7 UNODC (2017) Press release: ‘Extraordinary’ 60th session of the 
Commission on Narcotic Drugs closes with commitment to keep 
protecting people. Vienna: United Nations Office on Drugs and 




4 CND Blog (2017) Plenary – Agenda Item 6: Follow-up to the 
special session of the General Assembly on the world drug 
problem held in 2016, including the seven thematic areas of the 
outcome document of the special session (Thursday, March 16, 
2017 – Afternoon): Office of the High Commissioner for Human 





5 United Nations Development Programme (2017) Commission  
on Narcotic Drugs 60th Session, 13 to 17 March 2016, 
Vienna [UNDP statement made at Plenary Agenda Item 6]. 




and changes in 
national addiction 
treatment data
A new paper by Smyth et al. explores the relationship 
between changes in legislation related to new psychoactive 
substances (NPS) and their problematic use.1 In 2010, new 
psychoactive substances were the subject of two new 
pieces of legislation in Ireland. The first (enacted in May 
2010), expanded the list of substances controlled under the 
Misuse of Drugs Act 1977−1984 to include over 100 NPS.2 The 
second, the Criminal Justice (Psychoactive Substances) Act 
2010 (enacted in August 2010), differed from the established 
approach to drug control under Ireland’s Misuse of Drugs 
Act, in that it covered the sale of substances by virtue of 
their psychoactive properties, rather than the identity of the 
drug or its chemical structure. It was aimed at vendors of 
NPS and effectively made it an offence to sell a psychoactive 
substance.3 This ‘two-pronged legislative approach’ was 
largely in response to an increase in the number of so-called 
‘headshops’ selling NPS from late 2009 to a peak of 102 
premises in May 2010. By October 2010, only 10 headshops 
were still open and by late 2010 the Gardaí indicated that 
none of the remaining shops were selling NPS. 
Legislative bans such as these have attracted debate 
internationally as to their effectiveness in impacting on the 
overall availability and use of NPS, in particular problematic 
use.4 Smyth et al. explored whether ‘the arrival and 
subsequent departure of the headshops coincided with 
changes in presentation of problem NPS use among adults 
attending addiction treatment services in Ireland’. 
Methods
The paper is based on analysis of data from the National Drug 
Treatment Reporting System (NDTRS), an epidemiological 
database on treated drug and alcohol misuse in Ireland.5 It 
collects self-reported information on service users’ main 
problem drug and up to three additional problem drugs. 
Problem drug use is ‘generally understood [in the NDTRS] 
to equate to dependence or harmful use as described in 
ICD-10’. The system does not use a unique patient identifier 
and therefore the units of analysis reported on in the paper 
were treatment episodes, except where analysis focused on 
the cases of those never previously treated for drug use. A 
treatment episode was considered to be NPS-related, where 
a NPS was identified as a ‘main’ or ‘additional’ problem 
drug. A range of statistical analyses were carried out on the 
data, including odds ratios and jointpoint regression (further 
detail is available in the paper). To reflect the timeline of 
changes in problem NPS use in Ireland and the introduction 
of the relevant legislation, the paper examined episodes of 
treatment recorded in the NDTRS between 2009 and 2012 at 
four-month intervals.
Key findings
Key findings included that:
• NPS use can cause substance use disorders and create 
treatment demand. In what Smyth et al. called ‘the 
headshop era’ (i.e. January−August 2010), 4.2% of 
treatment episodes among 18–34-year-olds were 
NPS-related. This was compared to 2.4% of treatment 
episodes for the same age group over the three-year 
period 2009–2012.
• Between 2009 and 2012, the NPS group had a higher 
proportion of males when compared to the non-NPS 
group and had a younger age profile. The median age of 
the NPS group was 25 years compared to 35.6 years for 
the non-NPS group. 
• A decline in treatment episodes for NPS followed the 
enactment of the second piece of legislation that 
effectively ended ‘the headshop era’ in August 2010. The 
rate of NPS-related treatment episodes increased rapidly 
from the period September to December 2009, through 
early 2010, and peaked between May and August 2010. 
It decreased progressively after that point (see Figure 
1). Smyth et al. highlighted that the rate of NPS-related 
treatment episodes did not just ‘plateau’ following the 
enactment of the legislation causing the headshops to 
close,rather it ‘declined progressively by almost 50%’ 
over the subsequent two years. 
• Similar changes were not found for non-NPS related 











   













However, more recent data from the NDTRS show that NPS 
use is still problematic in Ireland and is showing a slight 
increase. While reported use of an NPS as a main drug of 
problem use among all age groups peaked in 2010, at 2.5% of 
all cases treated, and dropped to 0.4% of all cases treated 
in 2012, since then it has increased slightly to represent 0.9% 
of all cases treated in 2015.6 
Lucy Dillon
1 Smyth BP, Lyons S and Cullen W (2017) Decline in new 
psychoactive substance use disorders following legislation 
targeting headshops: evidence from national addiction 
treatment data. Drug and Alcohol Review, early online.  
http://www.drugsandalcohol.ie/27172/
2 Misuse of Drugs (Amendment) Regulations 2010. Available online at 
http://www.irishstatutebook.ie/eli/2010/si/200/made/en/pdf
3 Criminal Justice (Psychoactive Substances) Act 2010 
(commencement) Order 2010. Available online at  
http://www.irishstatutebook.ie/eli/2010/si/401/made/en/pdf
4 Dillon L (2016) New psychoactive substances: legislative changes in 
the UK. Drugnet Ireland, 59: 9−10. http://www.drugsandalcohol.
ie/26231/ 
5 For further information on the NDTRS, visit: http://www.hrb.ie/
health-information-in-house-research/alcohol-drugs/ndtrs/ 
6 Health Research Board (2017) Drug treatment in Ireland 
NDTRS 2009−2015. Dublin: Health Research Board. http://www.
drugsandalcohol.ie/27023 and http://www.hrb.ie/publications 
• While there was an overall decrease in NPS treatment 
episodes after August 2010, where they did occur, 
NPS stimulant powders accounted for an increased 
proportion of them, while the proportion of NPS 
cannabis-like substances declined. 
• The rate of NPS-related treatment episodes declined 
more acutely among young people who had never before 
sought addiction treatment, when compared to overall 
treatment episodes. 
• An NPS was the main problem drug in 39% of NPS-related 
treatment episodes in 2010, but this fell to 16% in 2012. 
Therefore, even though NPS continued to feature in 
treatment episodes after the headshops had closed, they 
were more likely to be a ‘peripheral problem’.
While acknowledging other possible explanations, the authors 
note that their findings ‘are consistent with a hypothesis that 
the legislation and consequent closure of the headshops 
contributed to a reduction in NPS-related substance use 
disorders in Ireland’. They concluded that:
While policy responses based on prohibition type 
principals appear to have fallen out of favour globally 
in the past decade, the experience of Ireland’s 
response to NPS suggests that such policies remain 
a legitimate component of society’s response to this 













































Non-NPS 12-month moving average
NPS 12-month moving average
9 6 16 114 122 87 101 80 65 67 51 38
NPS-related
episodes
Figure 1: Rate of addiction treatment episodes among 18–34-year-olds, from 2009–2012, comparing episodes related to new  
psychoactive substances to those related to other substances.
Headshop legislation and 
treatment data continued
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• However, more than two-thirds agreed that cannabis had 
a role to play in pain management (63.5%), treatment of 
multiple sclerosis (62.3%), and palliative care (68.5%).
• GPs with level 1 training for managing opioid users (n=86) 
agreed or strongly agreed that cannabis should be 
legalised for medical use (65%) and had a role to play in 
pain management (80%) and in multiple sclerosis (86%).
• GPs with level 2 training for managing opioid users (n=13) 
strongly agreed or agreed that cannabis should be 
decriminalised.
 
The qualitative analysis, which utilised a content analysis to 
examine the open-ended responses to the statements in 
section 2, resulted in five themes:2 decriminalisation and 
legislation debates; cannabis for therapeutic purposes; 
young people and family impacts; adverse health 
consequences; and legal status and comparisons to legal 
substances. 
Decriminalisation and legalisation debates 
These terms were often used interchangeably by GPs. 
The legalisation of drugs was seen as necessary by some, 
given that prohibition was perceived as not working. 
Decriminalising/legalising cannabis was viewed as a way 
to regulate and standardise the sale and production of 
cannabis, which would safeguard those that took cannabis. 
Decriminalisation was viewed as a way to reduce contact 
with dealers and reduce illegal income being generated 
from the sale of cannabis. Many GPs acknowledged the 
impact of using cannabis on mental health and the need to 
draw an evidence-based approach when trying to regulate 
the product.
Cannabis for therapeutic purposes (CtP) 
GP comments on prescribing cannabis for medical use were 
mixed. Concerns were raised over prescribing and patient 
misuse. Many commented on the lack of research evidence 
to support CTP and queried how comparable it was to other 
therapies. Although GPs acknowledged its potential for 
palliative and chronic illnesses and pain management, some 
argued that the risks of using it far outweighed the benefits.
young people and family impacts
The majority of GPs noted that using cannabis at a young 
age not only influenced the health and wellbeing of the 
young person but also influenced how well they did at 
school and their future career aspirations. Their families 
and the communities in which they lived also suffered. 
Concerns were raised over the level of mental illnesses, 
suicide attempts, and lack of engagement evident in this 
population. Drug education programmes were identified as 
a necessity to inform young people of the harms associated 
with cannabis use with the aim of preventing onset and 
progression to more risky drug-related behaviour. The 
potency of cannabis sold on the street troubled GPs, as 
it was a stepping stone towards using more potent illicit 
drugs, such as cocaine or heroin.
Irish GP  
attitudes towards 
decriminalisation 
and medical use of 
cannabis
The debate on the decriminalisation of cannabis and 
legalising cannabis for medicinal use has been ongoing in 
Ireland and abroad. Despite this, the topic has received 
scant attention in the research literature. A ‘unique’ and 
recent study carried out in Ireland aimed to build on existing 
interest in this area by examining the attitudes of Irish 
general practitioners (GPs) towards decriminalisation and the 
medicinal use of cannabis (n=565).1,2
Methodology
All GPs whose details were recorded on the Irish College of 
General Practitioner’s database were invited to participate 
in an online survey. The response rate was 15% (n=565). The 
survey contained three sections:
1  Closed questions were related to age, practice location, 
specialist level 1 or 2 registration,3 and experience in 
treating opioid users.  
2  To assess GP attitudes, participants were asked to 
agree to a series of statements using a five-point Likert 
scale; for example, ‘cannabis should be decriminalised’, 
‘cannabis should be legalised for medical use’, 
‘decriminalisation of cannabis use would lead to its 
increased use’ (p. 4). 
3  A series of open-ended questions that enabled 
participants to expand on the responses given in  
section 2.2
Results
The quantitative analysis, which examined responses by 
gender, age and training level, indicated that:1
• 56.8% of Irish GPs (n=320) in this study did not agree 
with decriminalisation of cannabis.
• Male GPs were more likely than female GPs to agree with 
the decriminalisation and legalisation of cannabis for 
medical use (p<0.0001 and p=0.002, respectively).
• GPs who were younger (<50 years) were more likely to 
agree with the legalisation of cannabis for medical use 
(p=0.044).
• GPs agreed that cannabis use has a negative impact on 
individuals with mental and physical health problems, 
82.7% and 60%, respectively. 
• GPS agreed that cannabis use can leave young people at 










   












17 Due to the poor response rate, it could be argued that the 
results of this study should be interpreted with caution. 
However, despite this limitation, the study makes a unique 
contribution and builds on existing knowledge, while also 
providing insight into the attitudes of GPs from an Irish 
context. One of the study authors, Dr Des Crowley, hopes 
that this study ‘will be considered within the ongoing debate 
on substance misuse in Ireland’.4
Ciara H Guiney
1 Crowley D, Collins C, Delargy I, Laird E and Van Hout MC (2017) 
Irish general practitioner attitudes toward decriminalisation 
and medical use of cannabis: results from a national survey. 
Harm Reduction Journal, 14(4): 4. http://www.drugsandalcohol.
ie/26675/ 
2 Van Hout MC, Collins C, Delargy I and Crowley D (2016) Irish 
general practitioner (GP) perspectives toward decriminalisation, 
legalisation and cannabis for therapeutic purposes. International 
Journal of Mental Health and Addiction: 1–14. doi:10.1007/
s11469-016-9710-2. http://www.drugsandalcohol.ie/27072/ 
3 Level 1 registration refers to GPs trained in addiction treatment 
but not to an advanced level. Level 2 registration refers to GPs 
with advanced addiction specialist training.
4 Irish College of General Practitioners (2017) Irish family 
doctors support legalisation of cannabis for therapeutic use. 
Available online at http://www.icgp.ie/go/about/policies_
statements/2017/51D12BC8-E89A-0F29-4D05611C1C784A5F.html 
Adverse health consequences
Many GPs emphasised that long-term cannabis use can lead 
to negative outcomes, such as dependence and mental 
health problems. GPs were conscious that some individuals 
were more susceptible to drug-induced psychosis or 
developing schizophrenia. Comments also centred on the 
challenges of treating cannabis use in mentally ill patients, 
particularly those that presented with suicidal ideation and 
self-harm. GPs stressed that better psychiatric services to 
support treatment were required. 
Legal status and comparisons to  
legal substances
GPs compared the after-effects of using cannabis with 
nicotine, alcohol and opioid pain relief, and purported that 
cannabis was less harmful but only if taken in moderation.
Limitations
As acknowledged by the authors, the response rate for this 
study was low (15%). This would suggest that the final sample 
may not be representative of the total GP population that 
were invited to participate in the survey.
Conclusion
The majority of GPs in this study are not in favour of the 
decriminalisation of cannabis drug policy, yet are in favour of 
legalising the use of cannabis for medicinal purposes. 
Irish gP attitudes continued
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PREVALENCE AND CURRENT SITUATION
Drug treatment figures 
from the NDtRS, 
2009–2015
The National Drug Treatment Reporting System (NDTRS) has 
published its latest figures on treated problem drug use 
(excluding alcohol).1 In the seven-year period 2009–2015, 
61,439 cases were treated for problem drug use (excluding 
alcohol). The number of cases rose from 7479 in 2009 to 
9892 in 2015. For the first time data from treatment in prison 
is included in annual figures. Of note, the data now include 
those cases with no fixed abode, no known address, or an 
address outside Ireland, in all tables, which were excluded 
from previous publications. Therefore, the data in this 
bulletin supersede all previously published data from NDTRS 
trend papers and web updates.
Service provider
The majority of cases were treated in outpatient facilities 
(64.4%) over the period, similar to previous years (Table 1). 
The proportion of cases treated in prison decreased slightly 
from 10.8% to 8.4% over the reporting period. The NDTRS 
has been collecting information on treatment in prison since 
2008, mainly from in-reach services (voluntary organisations 
providing counselling). However, since 2014, the Irish 
Prison Service’s addiction services in Mountjoy Prison have 
participated in the NDTRS, followed by the women’s prison, 
Dóchas, in 2015. In 2015, the proportion of cases treated in 
residential facilities increased for the first time in the period, 
from 14% in 2009 to 18% in 2015. 
overview
The proportion of new cases decreased over the period 
from 45.9% in 2009 to 37.8% in 2015, with a corresponding 
increase in the number of previously treated cases (Table 2). 
The increase in the number of previously treated cases is an 
indicator of the chronic, relapsing nature of addiction. 
In 2015, half of those treated were aged 30 years. Over 
the reporting period, the median age of all cases treated 
increased from 28 years in 2009 to 30 years in 2015. There 
were differences depending on whether the case was new 
(25 years) or previously treated (32 years). In 2015, most of 
those treated were male (72.2%) similar to previous years. 
The proportion of cases who were homeless increased from 
5.6% in 2009 to 9.2% in 2015.
For the first time, aggregated data on the numbers of 
cases from the Traveller community are presented in these 
routine statistics. The proportion of cases who identified as 
Travellers increased from 1.9% in 2009 to 2.9% in 2015. The 
proportion of Travellers in the general population is 0.7% (2016 
Census).2 In 2015, nearly two-thirds of all cases (64.4%) were 
unemployed. Unemployment rates in this group did not drop 
below 60% for all of the years reported. Unemployment rates 
were higher among previously treated cases.
Opiates (mainly heroin) continued to be the most commonly 
reported drug over the reporting period. While the number 
of cases treated for problem opiate use remained stable 
over the period, the proportion of cases treated decreased 
from 60.6% in 2009 to 47.8% in 2015. Cannabis was the 
second most common drug reported among those treated. 
The number of cases reporting problem cannabis use 
increased by 72%, from 1616 in 2009 to 2786 in 2015. Cocaine 
remained the third most common drug reported and in 2015, 
10.4% of cases reported problem cocaine use, the highest 
proportion reported since 2010. 
Another significant finding was the increasing proportion 
of cases reporting benzodiazepines as a main problem 
drug, which rose by 185% from 306 cases (4.1%) in 2009 to 
873 cases (8.8%) in 2015. In addition, the number of cases 
treated for Z-drugs has increased significantly from 9 in 
2009 to 154 in 2015.
Table 1: Number of cases treated for problem drug use, by type of service provider, NDTRS 2009–2015
2009 2010 2011 2012 2013 2014 2015
total 7479 8806 8361 8005 9006 9890 9892
Outpatient 5006 5563 5623 5299 5998 6251 5818
Inpatient* 1064 1232 1107 1124 1233 1348 1779
Low threshold 341 793 642 711 812 1190 1197
Prison 811 930 761 642 747 844 827
General practitioner 257 288 228 229 216 257 271
 
* Includes any service where the client stays overnight, e.g. inpatient detoxification, therapeutic communities, respite and step-down
Table 2: Number of cases treated for problem drug use, by treatment status, NDTRS 2009–2015
2009 2010 2011 2012 2013 2014 2015
Revised total 7479 8806 8361 8005 9006 9890 9892
New cases 3431 3741 3316 3272 3475 3776 3742
Previously treated cases 3891 4842 4862 4518 5239 5643 5855










   













For the first time, the bulletin reports on treated problem 
use of novel psychoactive substances (NPS). The number 
of cases treated for NPS use peaked in 2010, at 2.5% of all 
cases treated, and dropped to 0.4% of all cases treated in 
2012. Since then, it has increased slightly to represent 0.9% 
of all cases treated in 2015.
The majority of cases reported problem polydrug use (63.5%) 
over the period; however, the proportion has decreased 
from 68.4% in 2009 to 60.9% in 2015. Up to 2013, alcohol 
was the most common additional drug reported. Since 2014, 
benzodiazepines have become the most common additional 
drug reported. 
The proportion of all cases treated who reported ever 
injecting remained relatively stable over the reporting period 
at around one-third of all cases. The proportion of new cases 
reporting ever injecting has decreased from 19.7% in 2009 to 
14.5% in 2015. 
Suzi Lyons
1 Health Research Board (2017) Drug treatment in Ireland  
NDTRS 2009–2015. Dublin: Health Research Board.  
http://www.drugsandalcohol.ie/27023
2 Data on ethnicity is taken from the 2016 Census from the CSO. For 
more information, see http://cso.ie/en/media/csoie/newsevents/
documents/pressreleases/2017/prCensussummarypart1.pdf
drug Treatment figures 
2009–2015 continued
Table 1: Number and length of stay of alcohol-related discharges, 2006–2015
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
All persons 17,053 18,024 18,400 18,109 17,755 17,078 17,225 17,120 17,139 17,917
Males 12,629 13,344 13,579 13,254 13,015 12,457 12,552 12,398 12,435 13,128
Females 4424 4680 4821 4855 4740 4621 4673 4722 4704 4789
Average length of stay 8.1 8.0 8.8 8.6 9.1 9.4 9.2 10.1 9.9 10.8
% of bed days 3.2 3.3 3.6 3.5 3.6 3.7 3.6 3.6 3.6 3.8
Alcohol-related 
morbidity in Ireland
In 2016, the Health Research Board (HRB) published an 
overview of the situation in Ireland regarding alcohol 
consumption and harm and trends over time.1 This overview 
provided an analysis of alcohol-related discharges from 
1995 to 2013 that were wholly attributable (i.e. alcohol is a 
necessary cause for these conditions to manifest). The data 
were obtained from the Hospital In-Patient Enquiry (HIPE) 
scheme, which collects clinical and administrative data on 
discharges (including deaths) from acute Irish hospitals and 
is managed by the Healthcare Pricing Office (HPO) in the 
Health Service Executive (HSE). The purpose of this article is 
to update this analysis for the years 2014 and 2015. A detailed 
description of the methods undertaken in this analysis may 
be found in the 2016 overview.
Number of alcohol-related discharges
The number of alcohol-related discharges increased in 
2014 and 2015, with 17,917 recorded in 2015 (Table 1). The 
proportion of alcohol-related bed days has increased from 
3.2% in 2006 to 3.8% in 2015. In 2015, alcohol-related 
discharges accounted for 175,750 bed days, which means 
that each day 482 beds were occupied by people with a 
wholly attributable alcohol-related condition. There has also 
been an increase in the mean length of stay, from 8.1 days in 
2006 to 10.8 days in 2015, which suggests that patients with 
alcohol-related diagnoses are becoming more complex in 
terms of their illness. 
Discharges by gender and age
In 2015, males accounted for 73.3% of discharges and 
females for 26.7% of discharges. In general, female 
discharges were younger than male discharges. While males 
accounted for almost three-quarters of all discharges in 
2015, they only accounted for 49.2% of discharges aged less 
than 18 years, while females accounted for 50.8%. The age 
profile of discharges is presented in Figure 1. Discharges 
for both males and females peaked in the 50–59-years age 
group and 62% of all discharges were aged under 60 years. 
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In 2015, acute conditions accounted for 10.9% of alcohol-
related discharges; chronic diseases accounted for 20.7% of 
such discharges, while other chronic conditions accounted 
for 58.3%. Acute conditions were more prevalent among 
younger people, while chronic diseases and other chronic 
conditions were more common among older age groups. 
Alcoholic liver disease (ALD) was the most common chronic 
alcohol disease, accounting for four-fifths or 3293 of 
all alcohol-related chronic diseases in 2015. The rate of 
discharges with ALD increased from 76.1 per 100,000 adults 
aged 15 years and over in 2006 to 91.3 in 2015, an increase 
of 20.0% (Figure 2). Of all discharges with an ALD diagnosis 
in 2015, 8.1% died while still in hospital. The proportion of 
ALD discharges that died shows a similar pattern since 2006, 
which suggests that there has been little improvement in the 
prognosis of patients with ALD.
Conclusion
The number of alcohol-related discharges has increased 
slightly since 2013; however, the rate of discharges with 
a diagnosis of alcohol-related liver disease has increased 
by 4.1% since 2013, which is a cause for concern. Alcohol-
related morbidity continues to be a public health problem, 
with 482 beds being occupied each day by people with a 
wholly attributable alcohol-related condition. Given that this 
does not include alcohol partially attributable discharges 
(alcohol must be a component cause), such as some cancers, 
cardiovascular disease, and intentional and unintentional 
injuries, the true burden is likely to be much higher. These 
hospital data indicate that the measures outlined in the 
Public Health (Alcohol) Bill 2015 need to be implemented as 
soon as possible.
Deirdre Mongan
1 Mongan D and Long J (2016) Overview of alcohol consumption, 
alcohol-related harm and alcohol policy in Ireland. HRB 
Overview Series 10. Dublin: Health Research Board.  
http://www.drugsandalcohol.ie/25697/ 
Figure 2: Rate of alcoholic liver disease discharges per 100,000 adults, by gender, 2006–2015



















































































   























































Research presented at the National Health Services Research 
Institute Research Day1 by Dr Christina Dillon of the National 
Suicide Research Foundation (NSRF), which has recently 
been published in the Journal of Affective Disorders,2 
highlights the effect of alcohol consumption on self-harm 
presentations to Irish hospital emergency departments 
during public holidays.
The National Self-Harm Registry Ireland has consistently 
shown peaks in self-harm presentations out of hours at 
weekends and during public holidays. Presentations involving 
self-harm peak around midnight, and approximately 
one-third of presentations are recorded on Sundays and 
Mondays. Over recent years, peak attendances have been 
observed on public holidays. During the period 2007 to 2015, 
the mean number of self-harm presentations was 27 daily 
and 32 on public holidays. Across all years, St Patrick’s Day 
and New Year’s Day showed higher numbers of presentations 
compared to other public holidays, with a yearly average of 
44 and 41, respectively.
It was found that alcohol was involved in 43% of self-harm 
presentations on public holidays compared to 38% on all 
other days. Self-harm presentations had a 24% increased 
likelihood of involving alcohol on public holidays compared 
to all other days (relative risk: 1.24, 95% CI: 1.17–1.32). In 
addition, self-harm presentations to hospital on Christmas 
Eve, Christmas Day and New Year’s Eve had a 80%, 77%  
and 62% increased probability of involving alcohol, 
respectively (Figure 1).
The NSRF concludes that the findings support the hypothesis 
that self-harm presentations are elevated on public holidays 
and that alcohol consumption is more strongly associated 
with self-harm presentations on public holidays.
These findings highlight the need for continuing efforts to:  
• Enhance health service capacity at specific times. 
• Increase awareness of the negative effects of alcohol 
misuse and abuse. 
• Educate self-harm patients and their families about the 
importance of reduced use of, and access to, alcohol. 
• Arrange active consultation and collaboration between 
the mental health services and addiction treatment 
services in the best interests of patients who present  
with dual diagnosis (psychiatric disorder and alcohol/ 
drug abuse). 
• Ensure the assessment of alcohol misuse and abuse is a 
structural part of the assessment to determine the risk of 
repeated self-harm and suicide. 
Seán Millar
 
1 National Suicide Research Foundation (2016) Self-harm, alcohol 
consumption and public holidays. National Suicide Research 
Foundation newsletter, 15: 2. Cork: National Suicide Research 
Foundation. http://www.drugsandalcohol.ie/26645
2 Griffin E, Dillon CB, O’Regan G, Corcoran P, Perry IJ and Arensman 
E (2017) The paradox of public holidays: hospital-treated self-
harm and associated factors. Journal of Affective Disorders, 218: 
30-34. http://www.drugsandalcohol.ie/27285/
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Communities that 
Care: a review
The National Substance Misuse Strategy1 found that 
community mobilisation can be successful in bringing 
stakeholders together to develop alcohol and drug policies. 
Communities That Care (CTC): a comprehensive prevention 
approach for communities is a review of one such approach 
and was published as part of the EMCDDA Papers series.2
Community mobilisation/coalitions
‘Community mobilisation’ and ‘community coalitions’ are 
strategic approaches used to reduce substance use and 
other harmful behaviours. Broadly speaking, they refer to 
a process through which communities work together to 
take action and bring about change, working with a range of 
stakeholders from the public, statutory and private sectors 
to identify the changes they want to bring about in their 
area. Based on the best evidence available, the different 
stakeholders plan together how to bring about the desired 
changes. They then implement the plan and monitor its 
progress in reducing the target behaviours.3 
Communities that Care (CtC)
CTC is a US-developed system for mobilising communities 
to address young people’s health and behaviour problems, 
including substance use. According to the EMCDDA paper, 
it is essentially ‘a prevention operating system’ (p. 2) that 
provides a method for communities to assess the particular 
needs of their young people, coordinate the stakeholders, 
and select and implement suitable evidence-based 
programmes. The approach is based on the belief that by 
understanding the risk and protective factors experienced by 
the young people within the community, appropriate tested 
and effective prevention and early intervention programmes 
can be implemented to build on the protective factors and 
thus reduce problematic behaviours. 
the review
The EMCDDA paper reviews the evidence on the 
effectiveness of CTC programmes in preventing substance 
misuse in young people. The review was facilitated by the 
availability of ‘some good-quality studies with diverse 
results’, although most of the research comes from North 
America. Of the 18 studies included in the review, 12 related 
to the same randomised controlled trial (RCT) of a CTC 
project in the US. The paper provides an overview of the 
findings from two RCTs, a before-and-after study, two quasi-
experimental longitudinal studies with a comparison group, 
and an EMCDDA report on international organisations. The 
primary outcomes considered were a reduction in incidence 
and prevalence of alcohol and other drug use among 
young people; and the enhanced ability of communities in 
adopting, implementing with fidelity, and sustaining tested 
and effective prevention and early intervention programmes. 
Secondary outcomes sought were reductions in delinquency 
and other problem behaviours among young people. 
outcomes
The review’s analysis is described by the author as ‘limited’ 
by the lack of a meta-analysis (p. 4). Such a pooled analysis 
was not possible given the variation between studies in the 
outcomes measured, the statistical analysis methods used, 
and the quality of reporting. Instead, an overview of the 
findings from each study can be found in the paper. Overall, 
the findings were mixed. The authors concluded that the two 
RCTs, which were conducted in very different contexts (US 
and Australia), ‘do not provide conclusive evidence regarding 
the effectiveness of CTC, although they do strongly 
suggest a positive effect’ (p. 9). The strongest evidence of 
effectiveness by reducing the incidence and prevalence of 
delinquency and substance use for some cohorts came from 
the US-based RCT. 
transferability
The other studies reviewed were of Europe-based CTC 
projects. They were used to assess the transferability of CTC 
to Europe. A number of issues were identified, such as: 
• The very concept of ‘community’ differs between 
countries. While the community members of the coalition 
tended to be volunteers in the US, they were more likely 
to be paid professionals in some European projects. 
• The CTC sites in Europe were less rural and more 
heterogeneous than those in the US, and disadvantaged 
neighbourhoods were not as poor and their residents not 
as socially excluded.
• There is only a limited number of evidenced-based 
prevention programmes to draw upon in Europe 
compared to the US. 
• More lead-in time was required for projects, as 
participants were not always familiar with the concept of 
prevention programmes and their implementation.  
Conclusion
In conclusion, the review described CTC as a ‘useful 
preventative intervention in North America, but its 
effectiveness still needs to be clearly assessed in Europe’ (p. 
9). To do so would require a sufficiently robust randomised 
study to be supported, as well as the appropriate adaptation 
of the programme to fit the European context. 
Lucy Dillon
 
1 Department of Health (2012) Steering group report on a 
national substance misuse strategy. Dublin: Department of 
Health. http://www.drugsandalcohol.ie/16908/ 
2 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2017) Communities That Care (CTC): a comprehensive 
prevention approach for communities. EMCDDA Papers. 
Luxembourg: Publications Office of the European Union. http://
www.drugsandalcohol.ie/26931/
3 The findings of the evaluation of an Irish community mobilisation 
programme were reported in issue 58 of Drugnet Ireland. http://
www.drugsandalcohol.ie/25954/. See also Galligan C (2016) 
National community action on alcohol pilot project 2015: 











   












17 Drug misuse 
prevention:  
NICE guideline
The National Institute for Health and Care Excellence (NICE) 
in the UK published updated guidance on Drug misuse 
prevention: targeted interventions.1 The focus was on 
preventing or delaying ‘harmful use of drugs in children, 
young people and adults who are most likely to start using 
drugs or who are already experimenting or using drugs 
occasionally’ (p. 5). It was concerned with the use of illegal 
drugs, ‘legal highs’ and prescription-only medicines.
The guideline was aimed at a range of stakeholders: 
health and social care professionals; commissioners and 
providers; practitioners working in drug misuse prevention 
and specialist drug treatment services; owners and staff at 
venues where people using or at risk of using drugs attend; 
educational governance workers; drug users; their carers 
and families; and the public. The recommendations were 
based on the findings of an expert committee’s review of the 
evidence and submissions from experts working in the area. 
They considered both the effectiveness of the interventions 
in reducing drug use and their cost-effectiveness. If an 
intervention delivered on the former but was not cost-
effective, it was not recommended. Overall, the committee 
found limited evidence for the cost-effectiveness and 
effectiveness more broadly of drug misuse prevention 
interventions across the groups at risk.2
Assessment
Carrying out an assessment of the individual’s drug use was 
consistently found to be a part of effective interventions 
— this helped ensure that an appropriate intervention was 
offered. The committee recommended that people in these 
groups should be routinely and opportunistically assessed for 
vulnerability to drug use. This should be done as part of any 
appointments they might have with services such as health 
and social care services, and the criminal justice system. 
Children/young people assessed as  
vulnerable to drug misuse
Where children and young people were assessed as 
vulnerable to drug use, the committee recommended skills 
training for them and their carers or families. They did not 
recommend skills-based training for the young people alone 
or just their carers/families. This was found to be a more 
cost-effective way to reduce the risk of drug misuse than 
other interventions explored: family-based interventions, 
manualised/licensed programmes, or motivational 
interventions. They noted that skills training was likely to 
improve a range of drug-related and non-drug-related 
outcomes.
Components of effective skills training for children and 
young people included developing skills in listening, conflict 
resolution, refusal, managing stress, making decisions, coping 
with criticism, dealing with feelings of exclusion, and making 
healthy behaviour choices. For carers or families the skills to 
develop were: communication, developing and maintaining 
healthy relationships, conflict resolution, and problem 
solving. They recommended that age, developmental stage, 
vulnerabilities, cultural context, religion, and ethnicity should 
all be considered when deciding on the details of the skills 
training sessions.
Adults assessed as vulnerable to drug misuse 
There was not enough evidence of effectiveness and 
cost-effectiveness to be able to recommend skills 
training or motivational interventions for adults who had 
been assessed as vulnerable to drug misuse. Instead, the 
committee recommended that practitioners continued 
to deliver ‘current practice’. This was found to include 
brief information and education on drugs and their 
effects (including the health and social effects), with 
the opportunity for feedback. The committee also 
recommended that adults be given information on sources 
of advice and support if their risk of drug misuse increased. 
The information and other resources should be delivered at 
the time of assessment in both a written and verbal format. 
A plan for follow-up should also be made at the time of 
assessment.
People at risk of using drugs
The report also makes recommendations for working with 
people who are not in touch with services. In the absence 
of an evidence base of effective interventions, they 
recommend providing information about drugs and an online 
assessment and feedback tool. This could be web-based and 
use social media. However, written information should be 
provided to those who do not access online services.
Research recommendations
Given the weak evidence base for targeted prevention 
interventions, the committee recommended support for 
research on a number of topics, including: the long-term 
consequences of drug use, interventions for image and 
performance-enhancing drugs and new psychoactive 
substances; effectiveness of digital technologies in delivering 
prevention interventions; and acceptability of drug misuse 
prevention interventions among vulnerable groups.
Lucy Dillon
1 National Institute for Health and Care Excellence (2017) Drug 
misuse prevention: targeted interventions. NICE guideline 
[NG64]. London: National Institute for Health and Care 
Excellence. http://www.drugsandalcohol.ie/26887/
2 For the purpose of the guideline, ‘groups at risk’ were defined 
as including: people who have mental health problems; people 
who are being sexually exploited or sexually assaulted; people 
involved in commercial sex work; people who are lesbian, gay, 
bisexual or transgender; people not in employment, education or 
training (including children and young people who are excluded 
from school or who truant regularly); children and young people 
whose carers or families use drugs; children and young people 
who are looked after or care leavers; children and young people 
who are in contact with young offender teams but not in secure 
environments (prisons and young offender institutions); people 
who are considered homeless; people who attend nightclubs and 
festivals; and, people who are known to use drugs occasionally or 
recreationally.
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Drug supply reduction: 
an overview of EU 
policies and measures
In January 2017, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) published Drug supply reduction: an 
overview of EU policies and measures.1 This is an introductory 
guide to the European Union’s (EU) approach to drug supply 
reduction. A number of different strategies were presented. 
Policy areas
The main policy document that addresses drug supply 
reduction is the EU drugs strategy 2013–2020 and its action plan 
2013–2016.2,3 The main objective of the strategy is to reduce 
the availability of illicit drugs by disrupting illicit drugs trafficking 
and dismantling organised crime groups (OCGs) involved. An 
efficient criminal justice system is viewed as essential along with 
intelligence-led law enforcement and sharing of intelligence 
among agencies. From an EU perspective, the main focus 
is placed on organised, large-scale and cross-border drug-
related crime (p. 4). Drug supply reduction is also addressed 
in policies in other areas, for example, security, policy cycle 
(organised and serious international crime), maritime security, 
and regional programmes.

































Member states ★ ★ ★
 
Source: EMCDDA and Europol, 20164 
Note: EEAS: European External Action Service; COSI: Standing Committee 
on Operational Cooperation on Internal Security; HDG: Horizontal Working 
Party on Drugs; Eurojust: EU Judicial Cooperation Unit; Frontex: European 
Agency for the Management of Operational Cooperation at the External 
Borders of the Member States of the European Union; CEPOL: European 
Police College.
EU institutional system
EU structures involved in the design and implementation 
of strategies that aim to address drug supply include 
institutions, bodies and EU agencies (see Figure 1). Primarily, 
policy-making and legislative processes are carried out by 
the EU institutions, who along with council committees, 
working groups, EMPACT (European Multidisciplinary 
Platform against Criminal Threats) and EU agencies support, 
coordinate and implement the policies designed. 
Disrupting European drug markets
How drug trafficking routes are operated can raise security 
problems in the EU. The main responses identified in the 
paper to overcome the challenges that arise included: 
• Intelligence-led policing along with cooperation between 
the EU and its member states is considered essential to 
address organised crime in the EU. Although the main 
organisation that aims to reduce drug supply and target 
OCGs is Europol, collaborative work is carried out with 
Interpol and law enforcement agencies worldwide. To 
determine the level of threat, assessments are carried 
out using Europol’s Serious and Organised Crime Threat 
Assessment (SOCTA), which forms part of the EMPACT 
policy cycle.
• Legislation that aims to deter drug trafficking and 
apprehend OCGs has been put in place at an EU level and 
enables collaboration between member states to target 
cross-border criminal activities (see EMCDDA paper for a 
list of legislation implemented, Table 2, p. 8).1
• Chemicals (e.g. acetic anhydride) that are used in the 
manufacture of other products, such as perfumes and 
cosmetics, can also be used in heroin production. To 
ensure that chemicals are not used as drug precursors, 
regulations have been put in place at United Nation and 
EU levels to control and monitor their use. 
• A key priority identified in the European Agenda on 
Security (2015–2020)5 and the EU action plan on drugs 
(2013–2016)3 is to prevent OCGs from gaining access to 
drug-related profits. Current legislation exists to enhance 
judicial cooperation in cross-border money-laundering 
cases and for asset confiscation and recovery and money 
laundering. The European Commission works with various 
organisations (e.g. International Financial Action Task 
Force (FATF) and Expert Group on Money Laundering and 
Terrorist Financing) to build and instigate responses to 
money laundering.
• As part of the ongoing EU commitment to drug supply 
reduction, four types of programmes are funded: 
framework programmes; programmes for EU candidate 
and potential candidate countries; geographic or 
regional programmes; and programmes that complement 
geographic ones. 
• More often than not the main way to ship illicit drugs is by 
sea. This poses a serious challenge because the majority 
(70%) of the EU’s external borders are maritime. Maritime 
interdiction in the EU is centred on information-sharing 
networks, for example, Common Information Sharing 
Environment for Maritime Surveillance in Europe 
(Maritime CISE). Other systems that aim to address 
challenges include Consistently Optimised REsilient 
(CORE) ecosystem, European Borders Surveillance System 











   












17 drug supply reduction:  
an overview continued
targeting international drug trafficking
OCGs take advantage of existing international trade routes 
and national infrastructures to move illicit drugs via land, 
sea or air. With the aim of overcoming these challenges, 
the EU works with member states and other stakeholders 
on numerous programmes that target international drug 
trafficking, for example, the Container Control Programme, 
Cocaine Route and Heroin Route Programmes, Border 
Management, Paris Pact Initiative, Cooperation Programme 
on Drug Policies (COPOLAD) and the Global SMART 
(Synthetics Monitoring: Analyses, Reporting and Trends) 
Programme, by providing financial assistance via the 
European Commission for the United Nations Office on Drugs 
and Crime (UNODC).
Conclusion
The EU response to drug production and trafficking is 
ongoing and avails of a multifaceted interagency approach 
within and beyond Europe. The response is continuously 
evolving, as criminals alter methods used in drug production 
and trafficking in order to capitalise financially and prevent 
apprehension by law enforcement agencies. 
This EMCDDA paper provides a clear and concise overview 
from a global context of how the EU is responding to the 
unending challenges presented by the illicit drugs market and 
it would be a particularly useful resource for those already 
working in this area and for individuals new to it.
Ciara H Guiney
1 European Monitoring Centre for Drugs and Drug Addiction 
(2017) Drug supply reduction: an overview of EU policies and 
measures. Luxembourg: Publications Office of the European 
Union. http://www.drugsandalcohol.ie/26686/ 
2 Council of the European Union (2012) The EU drugs strategy 
2013–2020. Brussels: Council of the European Union.  
http://www.drugsandalcohol.ie/19034/
3 Council of the European Union (2013) EU action plan on drugs 
(2013–2016). Brussels: Council of the European Union. http://
www.drugsandalcohol.ie/20004/
4 EMCDDA and Europol (2016) EU drug markets report: in-depth 
analysis. Luxembourg: Publications Office of the European Union. 
Available online at http://www.emcdda.europa.eu/start/2016/
drug-markets#pane1/1
5 European Commission (2015) Communication from the 
Commission to the European Parliament, the Council, the 
European Economic and Social Committee and the Committee 
of the Regions — the European Agenda on Security, COM (2015) 




A typology of alcohol 
consumption among 
university students in 
Ireland
Elevated levels of alcohol consumption among university 
students are well documented, with research indicating a 
rise in alcohol use among students in Ireland and increasing 
levels of high-risk drinking.1 Policy-makers have attempted 
to combat this problem, as tailoring effective public health 
policy is crucial to tackling this burgeoning issue. Recently, 
typologies have been hypothesised as a pertinent public health 
tool. While traditional analysis methods tend to categorise 
individuals based on consumption profile alone, a typology 
approach may enhance an understanding of a societal 
phenomenon while making it possible to note patterns.
Recent research conducted by University College Cork aimed 
to develop a typology of alcohol consumption among the Irish 
university student population.2 In this study, published in the 
journal BMJ Open, hundreds of possible statements on types 
of alcohol consumption were generated from a systematic 
review and a set of one-on-one interviews. These were 
then reduced to 36 statements. Forty-three students were 
advised to scan through the 36 statements and fill them into 
a ‘forced choice, standardised distribution’. Following this, 
a 45–90-minute interview was conducted with students to 
illuminate subjectivity surrounding alcohol consumption.
A typology describing four distinct groupings of alcohol 
consumer was uncovered. These were:
• ‘Guarded drinker, careful spender, controlled 
enjoyment’: Characterised by students who enjoy 
socialising but only within the remit of social, family or 
cultural rules, which are self-regulated, and who described 
their alcohol consumption as cautious and light.
• ‘Calculated hedonists’: Students who indicated a 
hedonistic style of drinking. These students drank alcohol 
to feel pleasure, to enjoy themselves, to have fun and 
become drunk.
• ‘Peer influenced with an ulterior motive’: Students who 
focused on consuming alcohol as part of a group or at a 
party. These individuals were motivated by the sense of 
belonging they gain from alcohol consumption, indicating 
that drinking helps them to feel a part of the group and 
adds a sense of social confidence.
• ‘Inevitable bingers’: Students who described how 
they drink until all the alcohol they have is gone. These 
individuals noted self-inflicted dangerous situations 
arising from their own behaviours and drinking habits. 
As this was the first study to propose types of alcohol 
consumption based on a student’s own subjectivity, the authors 
acknowledge that future research will be required to investigate 
the degree to which each of these types is subscribed. 
Nevertheless, these profiles may provide a framework for 
public policy-makers and health promotion practitioners when 
tackling alcohol consumption at both a micro and macro level.
Seán Millar
1 Davoren MP, Shiely F, Byrne M, Perry IJ (2015) Hazardous  
alcohol consumption among university students in Ireland:  
a cross-sectional study. BMJ Open, 5(1): e006045.  
http://www.drugsandalcohol.ie/23350/
2 Davoren MP, Cronin M, Perry IJ, O’Connor K (2016) Alcohol 
consumption among university students: a typology of 
consumption to aid the tailoring of effective public health policy. 
BMJ Open, 6(11): e011815. http://www.drugsandalcohol.ie/26485/
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Drug-related intimidation (DRI) negatively impacts the health 
and wellbeing of individuals, families, communities and the 
functioning of local agencies who serve them. Intimidation 
can be explicit or implicit, involving actual, threatened 
or perceived threats of violence or property damage. It 
can leave targeted individuals feeling helpless, isolated, 
demoralised and fearful. The Health Research Board (HRB) 
recently published an evidence review, conducted on behalf 
of the Department of Health’s Drugs Policy Unit, to identify 
international best practice, community-based responses to 
DRI.1 The review focused on intimidation carried out by those 
involved in the distribution of drugs, including disciplinary 
intimidation, used to enforce social norms within the drug 
distribution hierarchy, to discourage or punish informants, 
or as a means to reclaim drug debt, and successional 
intimidation, used to recruit new members or gain control 
over networks or territory. 
The international literature evaluating direct responses to 
DRI was scant. Therefore, the review drew on three Irish 
studies describing the underlying structure and operation 
of Irish criminal and drug distribution networks to develop a 
conceptual framework for understanding potential pathways 
into DRI and potential intervention targets to disrupt this 
pathway (Figure 1). Despite using different methodologies 
in different Irish communities, these studies consistently 
described a three-tiered, hierarchical network structure 
involving: (1) a lower tier of highly disadvantaged young 
people generally involved in bullying, assaulting, stealing, 
vandalising, and spreading fear on behalf of the network; (2) 
a middle tier of young people typically engaged in high-risk, 
low-reward activities, such as transporting, holding or dealing 
drugs, carrying guns, and conducting shootings, beatings and 
serious intimidation; and (3) a higher tier of serious players, 
often formed around a kinship core. This framework suggests 
a number of potential intervention targets that differ in (a) 
their approach, whether based on a criminal justice or social 
inclusion perspective; (b) their target, whether they aim to 
prevent gang joining, prevent escalation in gang involvement, 
intervene to promote gang exit, or deter or suppress gang 
activity; and (c) the time horizon of their impact, whether 
short or long term.
Guided by this framework, the review sought to answer the 
following questions: 
What community-based interventions are effective in: 
 
1  Preventing entry into gang networks among at-risk 
children?
 
2 Promoting gang exit among gang-involved young people? 
 
3  Deterring or suppressing drug gang-related crime, 
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The review drew on gang control literature, which evaluates 
approaches to target the group processes and structures 
involved in perpetuating a cycle of community intimidation 
and violence. The premise of the review was that reducing 
gang activity by targeting the underlying structure and 
functioning of drug/gang networks directly would indirectly 
reduce the fear, intimidation and violence that they create in 
communities. 
Methods
The review team (a) systematically searched 10 bibliographic 
databases, the publication sections of key international 
organisation websites, and the reference lists of included 
studies; (b) screened 1251 records on title and abstract and 
136 on full text; and (c) included 45 reviews or studies in the 
final synthesis. The included literature was drawn from 12 
countries, predominately the United States. 
Findings
Gang prevention
Universal: Most universal prevention programmes identified 
were school based, with or without parental involvement. 
Collectively, effective programmes had positive effects on 
short-term outcomes, such as problem solving, empathy, 
conduct problems, antisocial behaviour, delinquency, 
aggression, and long-term outcomes such as substance 
initiation and use, violence and crime. Key features of 
effective programmes were those with positive goals, 
parental involvement, group-based and interactive 
techniques, trained professional facilitators, manualised 
content, and frequent content delivery. One gang-specific 
prevention programme (Gang Resistance Education and 
Training – GREAT II) showed promise in preventing gang 
membership; however, the evidence was drawn from only 
one large-scale study.  
Selective: Selective prevention programmes target 
those at higher than average risk and aim to prevent 
antisocial behaviour, substance use, delinquency and gang 
membership. A number of selective prevention programme 
models were identified. Good evidence suggests that skills-
based programmes targeting parents of at-risk children 
aged 0–3 years produce immediate short-term impacts on 
child behaviour and parenting practices and improvements 
in long-term delinquency outcomes. Youth mentoring had 
small beneficial effects on conduct and recidivism. There 
was no evidence available on the effect of education 
and employment opportunities provision for preventing 
gang involvement. Community sports programmes had 
weak evidence that they may reduce youth crime. There 
was strong evidence that deterrence or discipline-based 
programmes, such as Scared Straight or boot camps, are 
ineffective and potentially harmful. Selective prevention 
programmes shared the same key features as effective 
universal prevention programmes.  
Indicated: Indicated prevention programmes target 
individuals already engaged in high-risk behaviours, such 
as opposition behaviour, conduct disorder, antisocial 
behaviour, substance use and/or delinquency to prevent 
gang membership, gang embeddedness, and criminal activity. 
These include (a) therapeutic approaches: functional family 
therapy, multisystemic therapy, or multidimensional family 
therapy; and (b) gang-specific wraparound approaches, 
which are individualised programmes of care identifying the 
precise supports needed by an individual and their family and 
providing them for as long as needed. There is good evidence 
that indicated prevention programmes, incorporating 
therapeutic principles that aim to create positive changes in 
the lives of young people and their families, prevent negative 
outcomes. Risk assessment, using tools such as the Gang 
Risk of Entry Factors tool, ensures appropriate targeting of 
these programmes. 
Intervention (gang exit)
Gang alternatives interventions: Gang alternatives 
interventions seek to motivate gang-involved youth to 
leave their gang, support them in doing so, and create 
opportunities for meaningful occupation outside of the 
gang. Five identified gang alternatives interventions, involving 
street outreach or opportunities provision programmes, 
had limited evidence of no or negligible impact on gang 
membership status, gang-related crime or violence.  
In-depth analysis of desistance process: To address this gap 
in the available evidence, an in-depth analysis of primary 
peer-reviewed studies providing descriptive data — either 
qualitative or quantitative — on the nature or process of gang 
desistance was conducted. Analysis of this data suggested 
that gang members performed desistance work — they made 
an effort to reform their identity, pursue prosocial values, 
and seek belonging among prosocial groups. Gang exit 
requires this desistance work, which enables former gang 
members to become the primary agents in their exit from 
the gang. 
Suppression
Gang activity prevention: Gang activity prevention focuses 
on preventing the actions of gangs responsible for the most 
harm in the community by targeting specific activities, places 
or behaviours. Evidence for these approaches was limited in 
quantity and quality. Promising interventions in this category 
were carefully crafted civil gang injunctions, environmental 
design interventions, and urban renewal efforts. The latter 
had positive impacts on crime, while improving police 
legitimacy and communities’ sense of control and cohesion.  
Gang activity suppression: Gang activity suppression  
interventions seek to suppress or deter the harmful activities 
of gangs. ‘Pulling levers’-focused deterrence strategies 
had the largest direct impact on crime and violence of all 
suppression strategies reviewed. Key features of successful 
focused deterrence approaches include: targeting specific 
crimes rather than specific gangs; strong, swift and 
consistent enforcement actions, alongside meaningful 
offers of support by community agencies; establishing a 
multiagency task force to lead and coordinate the initiative; 
and engaging community members.  
Comprehensive approaches: Comprehensive gang control 
programmes, combining prevention, intervention and 
suppression, have shown promise but achieved mixed 
effects. Mixed effects have been attributed to poor model 
specification, poor implementation fidelity and an overly 
complex model given local capacity to coordinate and 
implement it. It is generally accepted that comprehensive 
approaches, designed within local capacity and resources, 
are likely to be the most appropriate approach to 
tackling gang-related crime, intimidation and violence in 
communities with acute gang problems.
drug-related intimidation continued
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Key messages
• Comprehensive approaches should be developed using 
the best available information on what works within each 
of the three domains — prevention, intervention and 
suppression. The reviewed literature suggests:
 –  Early intervention programmes involving schools 
and families, supporting positive goals, involving 
skills training, delivered by trained professionals and 
incorporating therapeutic approaches for those at 
higher risk according to risk assessment. 
 –  An assets-based approach to supporting the desistance 
work (efforts to reform identity and find belonging in 
prosocial groups) of gang members exiting their gang. 
 –  A ‘pulling levers’-focused deterrence strategy designed 
with community involvement. 
• Comprehensive approaches should be designed to 
be feasibly delivered at a consistent high quality and 
sustained over time within local financial resources and 
organisational capacity. 
• Any comprehensive approach requires stakeholder 
partnership among social services, schools, law 
enforcement, probation and parole, the courts system, 
and community representatives. Good coordination and 
communication is required to maintain this partnership.
• Engaging the local community and community leaders 
is important to the legitimacy of the effort. Community 
has a role to play in defining key issues, identifying young 
people who require support, designing responses, 
intervention delivery and increasing the legitimacy of the 
effort.
• Given the current state of the evidence, any approach 
that is implemented should:
 –  Have a theoretical underpinning 
 –  Be informed by local data 
 –  Be clearly articulated in advance
 –  Be implemented according to a protocol with 
deviations documented 
 –  Include a process and outcome evaluation 
• Lastly, researcher–practitioner partnerships may enable 
data-driven approaches, robust evaluation, and good 
implementation fidelity. 
Laura Murphy
1  Murphy L, Farragher L, Keane M, Galvin B and Long J (2017).  
Drug-related intimidation. The Irish situation and international 
responses: an evidence review. Dublin: Health Research Board, 
2017. http://www.drugsandalcohol.ie/27333
 
Laura Murphy, lead author of Drug-related intimidation. 
The Irish situation and international responses: an 
evidence review, left the HRB in June to take up a new 
post with the HSE. Laura is a superb researcher and 
brought a wide range of knowledge, analytical ability 
and original thinking to the task of leading this study on 
gang-related interventions. Laura’s contribution to the 
field is not just a valuable resource for Irish practitioners 
and policy-makers but also a significant addition to the 
international literature on this topic. We are sorry to 
lose such an able, sociable and supportive colleague, 






New clinical guidelines for opioid substitution treatment 
(OST) in Ireland have been published.1 They were developed 
by a working group comprising the Health Service Executive 
(HSE), the College of Psychiatrists of Ireland, the Irish College 
of General Practitioners, the Pharmaceutical Society of 
Ireland and HSE addiction services. The group reviewed all 
relevant national and international guidelines and consulted 
stakeholders in the addiction services. Professor Michael 
Farrell, director of the National Drug and Alcohol Research 
Centre at the University of New South Wales, provided 
expert opinion throughout the process.
This comprehensive document is divided into seven sections, 
each covering all different aspects of OST treatment: 
the guiding principles; rehabilitation and psychosocial 
components of OST; principles and key operational stages 
of pharmacological interventions of OST; assessment of 
dependence and management of OST; drug testing; OST and 
associated health considerations; and specific treatment 
situations and populations. 
The guidelines emphasise the importance of clinical 
governance and standards in OST treatment. Governance 
looks to put the service user first, working towards delivering 
a quality service and maintaining patient safety (see Appendix 
1, p. 70). The need for properly qualified and accredited staff 
to deliver the right interventions is also spelt out. 
There is an acknowledgment of the importance of family/
carers in the treatment process. The guidelines recommend 
that services should proactively engage with family/carers 
to enable them to be active partners in the treatment, with 
the service user’s consent. This is particularly important for 
teenagers. The guidelines also note that this group can have 
their own issues, distinct from the service user, which may 
need to be addressed. 
The document includes in-depth information for prescribing 
buprenorphine/buprenorphine-naloxone. The guidelines 
state that due to the safer profile of these formulations, 
induction and stabilisation can be quicker. They can be 
commenced by level 2 general practitioners (GPs) and HSE 










   












17 New clinical guidelines for oSt 
continued
Other recommendations include: 
• The first dose must not start until the service user 
experiences withdrawal symptoms (usually eight hours 
after last taking heroin or 24 hours after the last dose of 
methadone), as there is a risk of precipitated withdrawal. 
• Precipitated withdrawal occurs when buprenorphine 
displaces other opiates from the opioid receptors and, 
being a partial opiate agonist, this results in a rapid 
reduction of the effects of opiates, which in turn results 
in severe withdrawal symptoms.
• The recommended starting dose is between 4 mg and  
8 mg daily, which can be increased by between 2 mg to  
8 mg daily (usually 4 mg). 
• The dose can be increased up to a maximum of 24 mg 
for buprenorphine/naloxone or 32 mg for buprenorphine 
alone.
• The stabilisation phase for these drugs is usually between 
four to 6 weeks, shorter than methadone, usually 
between 16 mg and 24 mg.
• Maintenance on buprenorphine/buprenorphine-naloxone 
can be overseen by level 1 GPs.
• While it may vary with individual service user, a suitable 
maintenance dose will reduce or eliminate withdrawal 
symptoms and cravings over a 24-hour period.
• Once the service user is stable, the frequency of 
supervision and/or dispensing can be reduced, for 
example, buprenorphine-naloxone can be taken on 
alternate days (e.g. 8 mg daily dose can be taken as 16 mg 
on alternate days). However, the dose given on any one 
day cannot exceed 24 mg.
• All service users on long-term prescriptions should have 
regular care plan reviews (three monthly) within a wider 
treatment plan of social and psychological support.
• For detoxification, buprenorphine/buprenorphine-
naloxone can be reduced by 2 mg every 2 weeks. 
Detoxification from this formulation is often quicker than 
with methadone.
The guide states that evidence shows that contingency 
management (CM), for example using incentives such as 
take-home OST, is proven to improve outcomes in this patient 
group. However, it does have some disadvantages and it is 
therefore recommended that it be provided as part of a 
structured care plan in combination with other evidence-
based interventions. The guidelines directly address the issue 
of diversion. They state that take-home OST as an incentive 
for CM should be balanced against the known positive benefits 
to the service user and any potential risks, such as unsafe 
storage in homes or diversion. The criteria for deciding 
whether or not a client is suitable for take-home OST is based 
on known risk factors and an assessment of the individual 
service user and community safety, but also clinical stability. 
In the guidelines, clinical stability is defined as:
• Adherence with treatment directives
• No recent problematic drug or alcohol use
• Stable housing
• Stable dose of methadone (with allowances for 
occasional dose increases)
• Emotional stability and good insight into safety issues
Contraindications to receiving take-home OST are: 
• Repeated intoxication on presentation at the clinic/
pharmacy
• Children living in the patient’s household, with concerns 
that they may be at risk of harm
• Current chaotic and unpredictable behaviour
• Assessed as at risk of self-harm 
• Current hazardous use of drugs (including 
benzodiazepines or alcohol), as this can increase risks of 
fatal overdose
A brief summary of the entire guide contents and all key 
points are reproduced below.
1. Guiding principles
Contents: good governance; therapeutic alliance; and 
information sharing (p. 11). The key points are:
• OST plays an intrinsic role in supporting patients to 
recover from opioid dependence.
• OST should be provided at the lowest level of complexity, 
matching the patient’s needs, and as close to home as 
possible.
• Service users should be fully involved in the development 
of their care plans, setting goals and reviewing progress.
• It is good practice to involve service users in the design, 
planning, development, and evaluation of services.
• One of the strengths of drug treatment and rehabilitation 
in Ireland is the valuable partnership between statutory 
drug treatment services and the community/voluntary 
sectors. 
• Services should be proactive in their engagement with 
family members, with the recognition that they have 
distinct needs from service users.
• A good therapeutic alliance is crucial to the delivery of 
any treatment intervention.
2.  Rehabilitation and psychosocial 
components of oSt
Contents: OST as a component of rehabilitation; integrated 
care plans; psychosocial interventions; key steps involved in 
the integrated care pathway (p. 13). The key points are: 
• All drug users entering treatment:
 –  Should have a care plan based on assessed need, which 
is regularly reviewed.
 –  Should have full risk assessments to evaluate immediate 
health concerns, mental health issues, and risks to 
children.
 –  Should have their needs assessed across the domains 
of drug and alcohol use, health, offending, and social 
functioning.
• Key working is a basic delivery mechanism for 
interventions in addiction services.
• Psychosocial interventions:
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 –  Are a fundamental part of drug and alcohol treatment.
 –  Are the mainstay of treatment for the use of cocaine 
and other stimulants.
 –  Can also address common associated or co-occurring 
mental disorders, such as depression or anxiety.
• Self-help and mutual aid approaches have been found to 
be highly effective for some individuals.
• Contingency management (CM), Community 
Reinforcement Approach (CRA), Community 
Reinforcement Approach and Family Training (CRAFT)  
and Adolescent Community Reinforcement Approach 
(ACRA), and family and couples interventions should be 
offered, where appropriate. 
3.  Principles and key operational stages of 
pharmacological interventions for oSt 
Contents: aims and objectives of OST; legislative 
requirements for prescriptions and initiation of OST 
(including buprenorphine/naloxone); provision of information 
to the patient; communication between prescriber, 
dispensing pharmacist and multidisciplinary team; 
contingency management; diversion of opioid substitution 
medication; supervised consumption; ongoing assessment  
of OST; and referral procedure for change of OST location  
(p. 17). The key points are:
• Good communication between the patient, the 
prescriber, the pharmacist, and other members of the 
interdisciplinary team is crucial in providing optimal 
treatment.
• Carers should be active partners in drug treatment, 
where consent is given.
• Patients should be made fully aware of the risks of their 
medication and of the importance of protecting children 
from accidental ingestion.
• Prescribing, supervision, and dispensing arrangements 
should also aim to minimise risks to children.
• Supervision of methadone has been proven to reduce 
deaths related to overdose of methadone.
• Supervised consumption needs to be available for all 
patients for a length of time appropriate to their needs 
and risks.
• Ongoing assessment and care planning is central to the 
treatment process.
4.  Assessment of dependence and 
management of oSt 
Contents: Phase 1 assessing dependence; Phase 2 induction 
phase; Phase 3 stabilisation; Phase 4 maintenance; and 
Phase 5 detoxification (p. 26). The key points are:
• Methadone or buprenorphine, used at the optimal dose 
range, are both effective medicines for OST.
• Dose induction with methadone should aim to achieve an 
effective dose, while also exercising caution about the 
inherent risks of too rapid an increase.
• Dose induction with buprenorphine may be carried out 
more rapidly, with less risk of overdose.
• Clinicians should aim to optimise treatment interventions 
for patients who are not benefiting from treatment, 
usually by providing additional and more intensive 
interventions (pharmacological and psychosocial) that 
may increase retention and improve outcomes.
• Once stable on OST, at least one dose per week should 
be supervised.
• Methadone and buprenorphine are both effective in 
detoxification regimens.
• OST is a medical treatment and should not be used 
punitively, i.e. there should be no dose reduction as a 
sanction for ongoing illicit drug use.
•  Opioid detoxification should be offered as part of a care 
plan to patients ready for and committed to abstinence.
• Health professionals working in isolation must ensure 
they maintain up-to-date good practice.
5. Drug testing 
Contents: objectives of drug testing; rationale; procedures 
for testing; usefulness of drug testing; urine sample 
adulteration; supervision of urine samples; testing for alcohol 
and Z-drugs (p. 38). The key points are:
• Drug testing may be used as an ongoing tool for monitoring 
illicit drug use and adherence with prescribed medications. 
• Most drug testing processes consist of two separate types 
of analysis: a screening test and a confirmation test.
• The clinical situation will dictate the type of testing 
(screening or confirmatory) and frequency of testing.
• Once a patient reaches a stable point with OST, a 
reduction in frequency of drug testing is recommended.
• Drug testing should be randomised where possible.
• Direct observation of urine specimen collection is not 
required in routine clinical practice.
• The use of oral fluid drug testing is an acceptable 
alternative to urine drug testing.
• Drug testing results should be shared between treatment 
locations and agencies, with appropriate consent, to 
prevent the duplication of testing.
• Addiction services, including level 1 and level 2 GPs, 
nationally should have access to an appropriately 
accredited laboratory for drug testing / confirmatory 
analysis.
• Biological fluids should be handled with appropriate 
standard and transmission-based precautions.
• The recommendations for frequency of testing are to be 
viewed as a minimum standard for all patients receiving 
OST. In certain clinical situations, some patients may 
find that more regular testing may help them reach and 
maintain stability.
• Stability and safer prescribing of OST is assessed on a 
range of criteria, drug screening being one of those. 
There are limitations to the value of drug testing, and 
clinicians need to assess stability across a range of 
parameters.
6. oSt and associated health considerations 
Contents: responses to continued drug and alcohol misuse 
for patients; mental health; viral infections; vaccinations; 
health implications for continued drug and alcohol use; pain 
management for drug misusers; ECG monitoring; and drug-
related deaths (overdose, reducing drug-related deaths, 










   












17 • Effective, safe and responsive services for service users 
involve working together and with others in teams in 
primary care and/or secondary care.
• Interventions must be carried out by trained and 
competent people with a clear understanding of the 
impact of problematic drug use.
• Appropriate communication and transfer of information 
between professionals is vital to ensure seamless care in 
line with the HSE consent policy.
• Assessment and evidence-based care provided by a 
liaison or multidisciplinary team is appropriate in many 
cases.
• Quality of treatment should be consistent across the 
criminal justice system, including prisons.
• Drug users in hospitals will require interventions that 
facilitate their medical treatment and, if possible, 
improve their engagement with drug misuse treatment.
• Clinicians working with pregnant women should aim to 
support the woman in achieving drug stability in order to 
reduce the risk of neonatal abstinence syndrome (NAS).
• Young people are likely to require different interventions 
compared to adults, and healthcare professionals 
will require specific competencies to deliver these 
interventions.
• Information sharing, governance, policies and practice 
should include guidance for clinicians working with the 
parents of under 18-year-old service users.
• Older drug users are likely to have increased drug-
related and non-drug-related health needs. Drug users 
in pain will have needs for pharmacological and other 
interventions similar to non-drug users.
Suzi Lyons
1  Health Service Executive (2016) Clinical guidelines for opioid 
substitution treatment. Dublin: Health Service Executive. 
http://www.drugsandalcohol.ie/26573/
• OST should be provided with a range of other medical 
interventions.
• Psychosocial interventions can also address common 
associated or co-occurring mental disorders.
• Common mental health problems are frequent in people 
accessing addiction services. Interventions may need 
to be provided in addiction services, in conjunction 
with Community Mental Health Teams (CMHTs). Those 
with severe mental health problems should have care 
integrated with acute community-based secondary 
mental health services.
• Reducing potential harm due to overdose, blood-borne 
viruses, and other infections should be part of patient care.
• All drug users should be offered testing and vaccination 
against hepatitis A and B, where indicated. This 
discussion should be documented in the patient’s record.
• All drug users should be offered testing and appropriate 
treatment for hepatitis C and HIV infections.
• Retaining patients in high-quality treatment is protective 
against overdose. This protection may be enhanced by 
other interventions, including training drug users and 
their families and carers in the risks of overdose, its 
prevention, and how to respond in an emergency.
• Drug users who are also using alcohol in a problematic 
way should be offered alcohol treatments.
• Drug users who smoke tobacco should be offered 
smoking cessation interventions.
7.  Specific treatment situations  
and populations 
Contents: hidden harm; criminal justice system (Garda 
custody, Drug Treatment Court, probation, prison); opiate-
dependent patients in hospital; pregnancy and neonatal care; 
young people; older current and ex-drug users; and palliative 
care and life-limiting conditions (p. 57). The key points are:
New clinical guidelines for oSt 
continued
AskAboutAlcohol.ie
On 7 March 2017, the then Minister of State for Health 
Promotion Marcella Corcoran Kennedy TD launched the 
Health Service Executive’s (HSE) new website on alcohol 
– AskAboutAlcohol.ie. The website was created to provide 
clear and authoritative information on alcohol to the public, 
and is the first dedicated website dealing with alcohol to 
be created by a State body. It provides advice on low-
risk drinking limits and detailed evidence on the mental 
and physical impacts of alcohol. It also contains a drinks 
calculator so the public can understand exactly how much 
they are drinking and whether it is within low-risk limits. 
There is also information on available supports and guidance 
for anyone who wants to cut back on their drinking and for 
those with a family member who drinks excessively.
At the launch, Minister Corcoran Kennedy spoke about 
the evidence in relation to high-alcohol consumption and 
harm in Ireland and described AskAboutAlcohol.ie and the 
information campaign as ‘an important first step in enabling 
people to manage their own drinking … simple yet effective 
tools like the drinks calculator will empower people to 
assess their drinking habits and make informed choices to 
improve their health and wellbeing’. This was reiterated by 
Dr Stephanie O’Keeffe, HSE National Director for Health 
and Wellbeing, who said that many Irish people remained 
unaware their drinking may have fallen into harmful patterns, 
and that underestimation of amounts consumed remains a 
prominent trend among young people in particular.
AskAboutAlcohol.ie is also designed to work in tandem with 
public health legislation and planned regulatory changes on 
alcohol labelling, availability and pricing. The launch of the 
website has been complemented by a public information 
campaign through the media and online. Leaflets exploring 
how alcohol impacts different individuals and societal groups 
will be released shortly.
Deirdre Mongan
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Methadone detoxification schedule 2 
• Reduction of dosage by 10 mg per week down to 40 mg 
per day, after which the dosage should be reduced by  
5 mg per week. The reduction in dosage should be 
decided upon with the person, and there should be no 
more than one dosage change per week.
timeframe for detoxification from methadone
The rate and pace of dosage reduction for detoxification 
should be decided on a case-by-case basis, depending on 
the needs and wishes of the person. For people with dual 
addiction with a hypnotic (e.g. benzodiazepines or Z-drugs) 
and methadone, the protocols recommend that they should 
be detoxified off the hypnotic first, then methadone. There 
are no updates to the suggested detoxification schedules for 
benzodiazepines.
The aim of the protocols is to improve service delivery 
and ensure best possible practice for each person seeking 
a detoxification. This in no way precludes healthcare 
professionals providing additional supports to meet the 
needs of the person based on their particular circumstances: 
‘The Steering Committee fully recognises, and wishes to 
emphasise, the importance of local knowledge and expertise 
in ensuring successful delivery of services. There is nothing 
to prevent services mandating an individual or agency locally 
to promote and/or coordinate the new guidelines’ (p. 11). 
Suzi Lyons
1 Ana Liffey Drug Project (2016) National community 
detoxification: methadone guidelines. Dublin: Ana Liffey Drug 
Project. http://www.drugsandalcohol.ie/26888/ 
2 Ana Liffey Drug Project (2016) National community detoxification: 
benzodiazepine guidelines. Dublin: Ana Liffey Drug Project. http://
www.drugsandalcohol.ie/26889/ 








The Ana Liffey Drug Project has produced updated 
community detoxification protocols for both methadone and 
benzodiazepines.1,2,3 
One of the main changes is the removal of the need for 
the mandatory broker role in the community detoxification 
structure. Key to the detoxification process is a named key 
worker or healthcare professional to provide psychosocial 
support and a GP to provide the necessary initial assessment 
and medical support throughout the process. There is an 
emphasis on psychosocial support and the key work process 
in the updated documents. The issues of dual diagnosis and 
mental health in community detoxification are discussed. 
Other updates relate to suggested detoxification schedules 
for methadone. 
Methadone detoxification schedule 1 
• After stabilisation, dosage should be reduced every 
1−2 weeks, which will bring the person down to zero in 
approximately 12 weeks, typically a reduction of 5 mg. 
While some people may prefer to detox more quickly at 
the beginning, there is currently no evidence to support 
whether this is more effective than that of a slowly 
tapered dose. 
Evaluation of pilot 
stage of Pharmacy 
Needle Exchange 
Programme in Ireland
Pharmacy needle exchange  
in the Republic of Ireland
The current National Drugs Strategy aims to reduce harms 
arising from substance misuse and to reduce the prevalence 
of blood-borne viruses among people who inject drugs 
(PWID) through the expansion of needle exchange provision 
to include community pharmacy-based programmes. In 
October 2011, the Health Service Executive (HSE) rolled out 
the national Pharmacy Needle Exchange Programme, which 
is a partnership initiative between the Elton John AIDS 
Foundation, the Irish Pharmacy Union, and the HSE. 
Once pharmacies have signed a service level agreement with 
the HSE, their contact details are passed on to the relevant 
HSE services so that they can promote access to sterile 
injecting equipment at the participating pharmacies and 
accept referrals for investigation and treatment. There are 
pharmacies providing needle exchange in each regional drugs 
task force area, apart from those covering counties Dublin, 
Kildare and Wicklow, which are served by a mix of static and 
outreach needle exchange programmes. At the end of 2014, 
there were 115 pharmacies providing needle exchange.
In line with best practice, the Steering Group of the HSE 
Pharmacy Needle Exchange Programme commissioned 
Liverpool John Moores University — in partnership with 
Waterford Institute of Technology — to carry out an external 
evaluation.1 This study was undertaken to evaluate the 
three-year pilot stage of the programme and the progress in 










   












17 Pharmacy Needle Exchange 
Programme continued
It aimed specifically to: 
• Understand client and stakeholder satisfaction with 
needle exchange and attitudes towards, and experiences 
of, these services. 
• Provide information relating to safer injecting, safer 
sexual behaviour, and the prevalence of blood-borne 
viruses that can be compared to international literature 
and to data collected during future evaluations.
• Provide recommendations regarding the development 
and delivery of services and policy.
This article presents the methodology and main findings from 
this study.
Methodology
All pharmacies participating in the programme in April 2014 
were eligible to take part in the study, and staff were asked 
to complete an online survey. Pharmacy staff were also 
requested to opt in to additional parts of the research, 
including participating in an interview with a member of the 
research team. 
Pharmacies were provided with questionnaires that staff 
were requested to ask any client using the needle exchange 
programme to complete. Visits were made to five of the 10 
pharmacies participating in the programme that had the 
greatest number of monthly transactions, where needle 
exchange clients were approached and asked if they would 
like to participate in the study through an interview. A brief 
online consultation with stakeholders was also undertaken, 
examining their perceptions of the programme effectiveness, 




Experience of service provision 
Pharmacy staff reported a variety of successes. The service 
was described in interviews as quick and efficient, with 
minimal impact on the running of other pharmacy activities. 
However, uptake was viewed as sporadic in some sites, with 
comments around levels of heroin availability impacting on 
injecting rates. Increasing uptake was reported in some sites, 
but with no change in gender profiles. Although a majority 
of staff reported positively about the needle exchange and 
clients, negative impacts of the service identified by small 
numbers of staff included the risk of crime and undesirable 
behaviour in the pharmacy and surrounding area. In addition, 
where pharmacies were located within shopping areas, it was 
apparent that some local businesses and security objected 
to the needle exchange.
Engagement and trust in needle exchange 
The majority of staff surveyed believed they had engaged 
well with clients, although difficulties identified included 
a lack of interest in engagement from some clients. The 
exchange itself was described by the majority of interviewed 
staff as a quick process, with service users appearing 
anxious to leave the site. Lack of interaction was generally 
due to service user reluctance to engage and pharmacist 
lack of time. While it was noted that clients may like the 
speedy transaction, it was also recognised that this limits 
the opportunity to offer further intervention. First contact 
characterised by friendliness on the part of the pharmacist 
and frontline staff was viewed by many as being vital when 
initially developing positive and trusting relationships with 
service users.
Needle and equipment provision 
Pack size options were described by the majority of 
interviewees as optimising efficiency and discretion for 
the user. However, some staff observed that service users 
report that the needles and syringes provided are not the 
right size or right volume, and identified that needles for 
groin injecting would be a useful addition. Further potential 
additions to packs that were suggested by pharmacy staff 
included tourniquets and condoms. The needle exchange 
transaction itself was viewed as efficient, but in some 
instances hampered by poor dialogue between pharmacist 
and service users, as well as low return rates. 
Training and information needs
The most frequent response when staff were asked to 
identify methods to improve the service was the provision 
of more information through training about local services 
and helplines, as well as refresher courses in response 
to emergent drug issues and service needs. In particular, 
training regarding performance and image-enhancing drugs, 
such as steroids and melanotans, was commonly requested. 
The majority of pharmacies engaged with local community 
drug services and methadone clinics, but observed the need 
for greater visibility of services and referral routes.
Client-reported outcomes 
Client satisfaction with services 
The survey sample (n=74) included 23 females and 46 males, 
with five clients not reporting their gender, with a mean age 
of 32 years. The majority (88%) reported using heroin, with 
less than 15% reporting use of any other drug. Generally, 
PWID reported high satisfaction with service provision, 
including the injecting kits provided, pharmacy location, 
opening hours, staff knowledge and information provision. A 
minority of clients reported dissatisfaction with the attitudes 
of staff (24%) and privacy within the needle exchange (30%), 
with lower satisfaction on both criteria among females. 
Experiences of accessing the pharmacies were generally 
positive, with few comments around stigma associated with 
injecting drug use, or uncomfortable feelings on accessing 
the pharmacy. Participants were additionally satisfied with 
the confidential nature of the exchange. Pharmacy staff 
were viewed as friendly and polite, with the primary reasons 
stated for using specific pharmacies being related to 
location of the pharmacy and staff attitude.
Client behavioural outcomes 
Self-reported rates of hepatitis B, C and HIV diagnosis were 
7%, 22% and 5%, respectively. Approximately one-third of 
clients reported never having being tested for each of these 
blood-borne viruses. Almost half (49%) of the survey sample 
reporting having used a needle with which someone else had 
already injected, with 28% having done so in the past month. 
Females were more likely to have shared a needle ever, or 
in the past month, than males. Approximately half (47%) 
of clients reported having multiple sexual partners in the 
past month, including a small proportion with five or more 
partners (7%). A minority (39%) of clients reported always 
using a condom during sexual intercourse.
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Stakeholder survey 
Six stakeholders completed the survey, including 
representatives from drug services, the Irish Pharmacy 
Union, and outreach services. Overall, the programme was 
rated as being ‘very effective’ (n=3) or ‘somewhat effective’ 
(n=3). Key strengths identified included the increase in 
availability and accessibility of needle exchange services, 
and the impact of this on access to equipment and health 
professionals. Perceived weaknesses included difficulties 
encouraging returns, the need for a ‘pick and mix’ service 
as opposed to pre-prepared packs (which are not suitable 
for all clients), a lack of signposting to other services, and 
the identification of some stigma affecting needle exchange 
relations with local businesses and customers. 
Conclusions
Overall, the evidence from the study suggests that the 
Pharmacy Needle Exchange Programme is acceptable and 
accessible to PWID in Ireland, and largely supported by 
pharmacy staff. Nevertheless, despite these successes, a 
number of recommendations were suggested that might help 
improve service provision and further meet client needs. 
These were to:
• Provide a wider range of equipment or packs suitable for 
all clients. Additionally, the possibility of providing ‘pick 
and mix’ services, in addition to pre-prepared packs, may 
better meet client needs. 
• Develop integrated care pathways to link the exchange 
programme with other services for PWID, such as drug 
agencies and sexual health services. As more health 
interventions become embedded within the pharmacy, 
this is likely to become increasingly important to prevent 
pharmacies from becoming isolated from other related 
organisations providing services for injecting drug users. 
• Consider offering within-pharmacy testing for blood-
borne viruses. Where this is not possible, ensure that 
pharmacy staff have sufficient information on local 
services to enable efficient referral processes and 
signposting. 
• Increase frequency of training provision for pharmacy 
staff and include information about anabolic steroids, 
melanotans and associated performance and image-
enhancing drugs to help staff provide services to clients 
who inject these drugs. Training should be constantly 
reviewed to ensure that it is meeting the needs of 
pharmacy staff. The profile of PWID is likely to change, 
and therefore the knowledge and skill requirements of 
staff will change too, leading to the need for top-up 
training. 
• Ensure that staff have sufficient training and knowledge 
about drug use and health-related issues to confidently 
provide harm reduction advice and support. 
• Encourage (through training and information for staff) 
a consistent approach to increase returns and improve 
engagement with clients. Additionally, build on current 
work being undertaken regarding appropriate community 
responses to drug-related litter. 
• Oversee the transition from a paper-based monitoring 
system to an electronic data monitoring system to be 
used by all participating pharmacies. 
As well as these recommendations, the authors suggest that 
future evaluations should use the same survey procedures 
to allow comparison on outcomes as an indication of 
programme development. In addition, the possibility 
of collecting biological samples from clients was also 
mentioned. 
Seán Millar
1 Bates G, van Hout MC, Hearne E, Mackridge A and McVeigh J 
(2015) Evaluation of the pilot stage of the Pharmacy Needle 
Exchange Programme in Ireland. Liverpool: Liverpool John 
Moores University. http://www.drugsandalcohol.ie/26905 
Pharmacy Needle Exchange 
Programme continued
outcomes for drug 
misuse treatment:  
an evidence review
In January 2017, Public Health England (PHE)1 published An 
evidence review of the outcomes that can be expected of 
drug misuse treatment in England.2 PHE was commissioned 
by the Department of Health in England to ‘review the 
evidence on: what can be expected of the drug treatment 
and recovery system and provide advice to inform future 
policy’ (p. 12). 
To meet this aim, they covered a number of topics related to 
drug treatment in England:
• The nature and prevalence of drug misuse and how drug 
treatment evolved to address it
• The outcomes achieved to date by the treatment system
• The international literature on treatment effectiveness 
and how England compared to other countries
• How housing, unemployment and social deprivation 
impact on treatment outcomes 
• The changing profile of the drug treatment population
• How to improve treatment outcome measures
A recurring theme throughout the report was that ‘indicators 
that are used to manage and commission drug treatment 
can have a powerful impact on how services are developed 
and on how resources are allocated locally’ (p. 115). The 
authors therefore called for ‘caution’ (p. 132) when selecting 
indicators to ensure the risk of generating unintended 
consequences was minimised. Indeed, they noted that 










   













Approach to the review
The work was overseen by an expert reference group 
made up of a variety of stakeholders: academics, service 
commissioners and providers, and experts by experience 
(service users). PHE took a mixed methods approach to the 
review: they used focus groups with service users; statistical 
analysis of the National Drug Treatment Monitoring System 
data; and a series of evidence reviews using a rapid evidence 
assessment method. 
treatment outcomes in the literature
In their review of the international literature, the authors 
found that a broad range of outcomes were used to 
measure treatment effectiveness. These included drug use; 
abstinence; drug injecting; overdose; mental and physical 
health; mortality; crime; and social functioning indicators 
such as employment, housing, family relations, and service 
users’ perceptions of their recovery. The breadth of these 
measures was taken to reflect the broad range of harms 
caused by drug misuse and, in turn, the benefits that could 
be expected by users entering treatment and addressing 
their drug use. In terms of the cost-effectiveness of 
treatment, estimates in the literature suggested a net 
benefit–cost ratio of approximately 2.5 to 1. For every £1 
spent on treatment, there was a £2.50 benefit to society. 
Social factors
The link between social deprivation and drug use is well 
established. The review found that social factors also 
influenced treatment outcomes. Unemployment and housing 
problems had a ‘marked negative impact’ on treatment 
outcomes and increased the risk that someone would 
relapse after treatment. 
Changes in treatment population
The review used modelling to estimate the likely size, 
characteristics, and needs of the treatment population over 
the next 4 years. Two changes in particular were expected 
to have implications for services and the measurement of 
their outcomes. First were changes in the profile of drugs 
for which treatment was being sought. Increases in the use 
of new psychoactive substances and prescription drugs 
were expected to continue. Second was the ageing profile 
of opiate users in treatment. Older heroin users (aged 40 
and over) accounted for an increasing proportion of those in 
treatment, and the authors estimated that this proportion 
would continue to grow over the coming years. This cohort 
have entrenched dependence over a long period of time 
and their needs are complex. They experience cumulative 
physical and mental health conditions as well as being 
more susceptible to overdose. The reviewers argued that 
stakeholders should maintain a ‘realistic recovery ambition’ 
for this cohort, accepting that they were less likely to 
complete treatment than ‘newer’ users. 
Indicators
The authors make a number of recommendations for the 
improvement of local and national drug treatment outcomes 
and their indicators. At the time of the review, the primary 
treatment outcome in England was the sustained successful 
completion of treatment. ‘Successful completion’ was 
defined as where a user had left treatment free of their 
dependence, was not in receipt of an opiate substitute, and 
did not re-present for treatment for 6 months. Based on the 
findings of the review, it was recommended that this period 
be extended to 12 months to ensure that post-treatment 
recovery support be maintained.
It was recommended that drug treatment indicators for 
opiate users be segmented into those for ‘new users’ and 
those for the older more chronic cohort of users. This would 
allow for the fact that it is much harder to effect change 
among long-term users who have very entrenched patterns 
of use and complex health and social needs, when compared 
to opiate users who engage with treatment after a shorter 
period of opiate use. It would allow for an increased focus 
on providing the older cohort with access to the primary and 
specialist healthcare services they might need. 
More generally, the report concluded that drug treatment 
outcomes should be expanded to better reflect the breadth 
of the benefits of drug misuse interventions. In summary, 
they suggested developing a set of indicators around the 
following: waiting times for treatment; the proportion of 
opiate and crack users in treatment; illicit opiate use in 
treatment; drug-related deaths and drug-related hospital 
admissions; incidence of blood-borne viruses; offending 
behaviour; treatment entry rates following prison release; 
employment status; and housing status.
Lucy Dillon
1 Public Health England is an executive agency of the Department 
of Health in England. It offers advice and support to their 
government, local authorities and the National Health Service, 
based on ‘world-class science, knowledge and intelligence, 
advocacy, partnerships and providing specialist public health 
services’. For more information on PHE, visit https://www.gov.
uk/government/organisations/public-health-england/about
2 Burkinshaw P, Knight J, Anders P, Eastwood B, Musto V, White MJ 
and Marsden J (2017) An evidence review of the outcomes that 
can be expected of drug misuse treatment in England. London: 
Public Health England. http://www.drugsandalcohol.ie/26696/
outcomes for drug  
misuse treatment continued
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Drinking pattern and alcohol harms
Participants who abstained from alcohol were more 
supportive of health professionals asking patients about 
their drinking behaviours as standard practice. Respondents 
who were heavy drinkers were less supportive of alcohol 
screening in primary care, general hospitals, and maternity 
services. Those who reported one or more of seven negative 
consequences due to their own drinking were also less 
supportive of alcohol screening by health professionals in 
general hospitals and in maternity services. Nevertheless, 
even among heavy drinkers, the majority (70%–86%) were in 
favour of health practitioners asking about drinking habits.
Availability and adequacy of alcohol  
treatment services
Just 4 in 10 respondents agreed that alcohol treatment 
services were available in their local health service area, 
while a similar number (43%) were unaware (don’t know) 
if alcohol treatment services were available (Figure 1). In 
addition, only 1 in 5 agreed that alcohol treatment services 
were adequate, 1 in 4 believed treatment services were not 
adequate, and over one-half were unsure. Subjects who 
lived in Dublin were significantly (p<0.01) less aware of the 
availability of alcohol treatment services in their local health 
service area when compared to subjects in other regions, 
with two-thirds saying they did not know if treatment 
services were available.
Conclusions
The results from these surveys suggest that most Irish adults 
are supportive of alcohol screening in a healthcare setting. 
However, the findings also indicate that a high percentage of 
survey respondents were unaware of availability of alcohol 
treatment services in local health areas. The authors suggest 
that these findings will be relevant in the planning of future 
services in relation to alcohol. Effective delivery of alcohol 
screening, and early intervention, may help reduce the 
burden and associated cost of alcohol-related problems in 
Ireland.
Seán Millar
1 Hope A and Barry J (2016) Alcohol treatment services in Ireland: 




services in Ireland: 
how the public  
view them
The Health Service Executive (HSE) has recently published 
findings from a study which examined the level of public 
support in Ireland for alcohol screening in healthcare 
settings, and to assess if alcohol treatment services are 
deemed available and adequate.1 The study was based on two 
cross-sectional national drinking surveys conducted in 2006 
and 2010. For the purpose of this research, the two survey 
data sets were combined (n=2011) to allow for detailed 
analysis. 
A similar methodology was used across the two surveys, that 
of a national quota sample of adults aged 18 years and over, 
using face-to-face interviews. The response rate was 62%. 
Several main findings from the study are discussed below.
Alcohol screening in healthcare settings
A majority of survey respondents agreed that intervention 
by health professionals regarding patients’ drinking habits in 
different healthcare settings should take place. The highest 
level of support for asking patients about their drinking 
behaviours as standard practice was in maternity services 
(91%), followed by general hospitals (84%), and in primary 
care (80%). 
Demographics
A higher percentage of married people (82%) in comparison 
to single people (77%) agreed that general practitioners (GPs) 
should ask all patients about their drinking habits as standard 
practice. Across regions of Ireland, those living in Dublin 
were less supportive of GP intervention in comparison to the 
rest of Leinster (79% vs 87%). More women than men (86% 
vs 82%) were supportive of alcohol screening; respondents 
who were younger were less supportive. Support was higher 
among those from lower socioeconomic classes (87%) in 
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17 The report suggested that Ireland could comply with best 
international practice by ensuring that the present prison-
administered healthcare services form close links with the 
HSE. However, Judge Reilly also stated that the Department 
of Justice and Equality have acknowledged that the 
international trend is now towards a service that is within 
the responsibility of the Department of Health, and that 
the Committee of Ministers of the Council of Europe, in its 
official commentary to the revised and updated European 
Prison Rules 2006,3 states: 
The most effective way of implementing Rule 40 
[organisation of healthcare] is that the national 
health authority should also be responsible for 
providing health care in prison, as is the case in a 
number of European countries. 
Judge Reilly noted that there may well be resource issues 
in transferring responsibility for prisoner healthcare from 
the IPS to the HSE and the Department of Health. However, 
he also stated that this cannot be used as an excuse for 
delaying such a transfer of responsibility. The report stressed 
that it must be borne in mind that the State accepts a 
heavy responsibility when it detains a person to ensure 
the wellbeing of that person, and that it is internationally 
acknowledged that a lack of financial means cannot reduce 
this responsibility.
Necessity of carrying out health needs 
assessment of prisoners and staffing needs 
analysis in each Irish prison
The report stated that irrespective of which body is 
responsible for healthcare in Irish prisons, be it the IPS or 
the HSE, a comprehensive assessment of the healthcare 
needs of prisoners in the 13 prisons in the Republic of Ireland 
must be undertaken. This must be followed by a staffing 
needs analysis of healthcare personnel within each prison. 
Judge Reilly noted that no such assessment has ever been 
undertaken within Ireland, and that it was impossible to 
express a view on the adequacy of the healthcare currently 
provided in Irish prisons, as it seemed to operate on an ad 
hoc basis.
Judge Reilly recommended that a Director of Healthcare, 
who is a registered healthcare professional, should be 
appointed immediately. The duty of the director would be 
to manage the healthcare in prisons and to oversee the 
transition of healthcare from the IPS to the HSE. The report 
also stated that the provision of healthcare in Irish prisons 
should not be confined to that which is provided by doctors 
and nurses, but should embrace all aspects of care, including 
addiction, psychiatric and psychology services.
Guidance to IPS on what will be expected 
of them in area of healthcare when future 
inspections are carried out 
The report indicated that at any time upon request, prison 
governors and/or healthcare staff should be in a position to 
make the following available to inspecting officials:
Healthcare in  
Irish prisons
A report entitled Healthcare in Irish prisons, prepared by 
the Inspector of Prisons, the late Mr Justice Michael Reilly, 
was presented to the Tánaiste and Minister for Justice and 
Equality on 25 November 2016.1 There were three specific 
aims of the report: 
• To point out the absolute entitlement of prisoners to 
healthcare and the case for such healthcare to be 
provided by the Department of Health.
• To point to the necessity of carrying out a health needs 
assessment of prisoners and a staffing needs analysis in 
each Irish prison.
• To give guidance to the Irish Prison Service (IPS), to the 
management of prisons, and the providers of healthcare 
in the prisons on what will be expected of them in the 
area of healthcare when inspections are carried out in 
the future.
obligation to provide healthcare in prisons 
equivalent to that in non-prison community
The report stressed that the right to health is a fundamental 
right and that Article 12(1)2 of the International Covenant 
on Economic, Social and Cultural Rights urges state parties 
‘to recognize the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health’. 
In addition, it is generally accepted as international best 
practice that the provision of healthcare in prisons should be 
equivalent to that available in the non-prison community. 
Entitlement to health services in the Republic of Ireland 
is primarily based on residency and means. In particular, 
eligibility to access health services depends on whether 
a person is a medical card holder or not. It is well 
established that a majority of prisoners come from lower 
socioeconomic sectors of communities, and that many 
present with mental health and other preexisting health 
problems often resulting from a chaotic lifestyle. Therefore, 
the report urged that healthcare should be provided to 
prisoners on the basis that they are entitled to the same 
treatment and choices as people in the free community 
who are in receipt of medical cards.
Healthcare services in Irish prisons are, in the main, 
provided by the IPS. An exception is the provision of in-
reach mental health psychiatric services by the Central 
Mental Hospital, which come at no cost to the IPS, as this 
service is funded by the Health Service Executive (HSE). 
Doctors are engaged either on a full- or part-time basis. 
The report noted that the recruitment of full-time doctors 
is proving difficult. As a result, the IPS are over-reliant 
on locum doctors, who by their nature are transitory, to 
provide medical services to prisons. Nurses are employees 
of the IPS and as such are answerable to the governors of 
the prisons to which they are attached.
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• The number of cancellations of appointments with 
external consultants, with reasons for such cancellations, 
for a given period.
Seán Millar
 
1 Reilly M (2016) Healthcare in Irish prisons. Dublin: Department 
of Justice and Equality. http://www.drugsandalcohol.ie/26885/ 
2 United Nations Human Rights Office of the High Commissioner 
(1966) International Covenant on Economic, Social and Cultural 
Rights. http://www.ohchr.org/EN/ProfessionalInterest/Pages/
CESCR.aspx
3 Council of Europe (2006) Commentary to Recommendation 
REC(2006) 2 of the Committee of Ministers to member states on 
the European Prison Rules. In European Prison Rules. Strasbourg: 
Council of Europe Publishing. https://rm.coe.int/16806f3d4f 
• The health needs assessment for the prison. 
• The staffing needs analysis for the prison. 
• The number of nurses, doctors, psychiatrists, dentists, 
other specialists, psychologists, auxiliaries, etc. (engaged 
full-time or part-time) and their hours of duty. 
• The number of medical referrals to hospital emergency 
departments for a given period. 
• The average time for transfer of prisoners to emergency 
departments, with the longest and shortest time, for a 
given period. 
• The number of medical referrals to external consultants 
for a given period. 
Healthcare in Irish prisons continued
HRB National Drugs 
Library launches  
new website
The HRB National Drugs Library is a free, open-access 
resource providing a unique collection of Irish and 
international research evidence relating to drug and alcohol 
misuse. You can access our resources and services through 
our newly redesigned website at www.drugsandalcohol.ie. 
As well as our online course directory and search facility,  
we have three main sections.
The key Irish data section draws together the latest 
information on the Irish situation, with treatment, prevalence 
and deaths data, factsheets, key reports and newsletters.
The practitioner portal makes it easier for those working in 
the drugs and alcohol area to find publications of particular 
interest to them. You may access pages by profession or 
subject of interest.
 
The third section of our new website, research evidence, 
reflects the need for practitioners, policy-makers and 
researchers to access key international reports, guidelines 
and resources. We have also added a glossary and resources 
for undertaking and critically appraising research. 
Our aim is to enable those involved in health and social 
care, education, and research to make evidence-informed 
decisions. We hope that our resources will provide quick and 
easy access to the latest best evidence.
Key Irish Data Social Workers
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The following abstracts are cited  
from published journal articles 
recently added to the repository  
of the HRB National Drugs Library  
at www.drugsandalcohol.ie 
PoLICy AND LEGISLAtIoN
Correlation between tobacco 
control policies, consumption of 
rolled tobacco and e-cigarettes, 
and intention to quit conventional 
tobacco, in Europe 
Lidón-Moyano C, Martín-Sánchez JC, 
Saliba P, Graffelman J and  
Martín-Sánchez JM (2017)  
Tobacco Control, 26: 149-152. 
http://www.drugsandalcohol.ie/25209/ 
Aims: To analyse the correlation 
between the implementation of 
tobacco control policies and tobacco 
consumption, particularly rolling 
tobacco, electronic cigarettes 
(e-cigarettes) users and the intent to 
quit smoking in 27 countries of the 
European Union.
Conclusion: The level of smoke-free 
legislation among European countries 
is correlated with a decrease in the 
prevalence of smoking of conventional 
cigarettes and an increase in the intent 
to quit smoking within the past 12 
months. However, the consumption of 
other tobacco products, particularly 
hand-rolled tobacco, is positively 
correlated with TCS among former 
cigarette smokers. Therefore, tobacco 
control policies should also consider 
other tobacco products, such as 
rolling tobacco, cigars and pipes. 
PREvALENCE AND  
CURRENt SItUAtIoN
Decline in new psychoactive 
substance use disorders following 
legislation targeting headshops: 
evidence from national addiction 
treatment data 
Smyth BP, Lyons S, Cullen W (2017) 
Drug and Alcohol Review, Early online 
http://www.drugsandalcohol.ie/27172/ 
The aim of this study was to ascertain 
if legislation that caused the closure of 
headshops had an impact on the rate 
of NPS use disorders.
Conclusion: Over the 2 years after 
the enactment of prohibition-
styled legislation targeting NPS and 
headshops, the rate of NPS related 
addiction treatment episodes among 
young adults declined progressively 
and substantially. We found no 
coinciding trend change in the rate of 
episodes linked to other drug groups.
Factors associated with different 
smoking status in European 
adolescents: results of the  
SEyLE study 
Banzer R, Haring C, Buchheim A, 
Oehler S, Carli V, Wasserman C,  
Kaess M, Apter A, Balazs J, Bobes 
J, Brunner R, Corcoran P, Cosman 
D, Hoven CW, Kahn JP, Keeley 
HS, Postuvan V, Podlogar T, Sisask 
M, Varnik A, Sarchiapone M and 
Wasserman D (2017) European Child & 
Adolescent Psychiatry, Early online  
http://www.drugsandalcohol.ie/27139/ 
The aim of the presented analysis 
was to investigate risk and influencing 
factors for different smoking status in 
a big sample of European adolescents. 
Conclusion: Our data show that 
smoking among adolescents is still 
a major public health problem and 
adolescents who smoke are at higher 
risk for mental problems. Further, 
adolescent smoking is associated with 
broken home families and parental 
behaviors. Therefore, early preventive 
measures are necessary not only for 
adolescents, but also for their parents.
Alcohol consumption among 
university students: a latent  
class analysis 
Davoren MP, Dahly DL, Shiely F and 
Perry IJ (2017) Drugs: Education 
Prevention and Policy, Early online  
http://www.drugsandalcohol.
ie/27020/
The aim of the current research was 
to use latent class analysis to employ a 
person centred approach to describe 
alcohol consumption among university 
students with particular reference  
to gender.
Conclusion: Both men and women 
reported a class of ‘Guarded Drinkers’, 
‘Responsible Conformers’ and 
‘Realistic Hedonists’. 
The remaining class of women was 
described as ‘Peer-influenced 
drinkers’. Identifying consumption 
typologies provides those working on 
tackling excessive alcohol consumption 
with profiles to implement tailored 
health promotion strategies.
the country-level effects of drinking, 
heavy drinking and drink prices 
on pre-drinking: an international 
comparison of 25 countries 
Labhart F, Ferris J and  
Winstock A (2017) Drug and  
Alcohol Review, Early online 
http://www.drugsandalcohol.
ie/27039/ 
The aim of this study was to model the 
impact of the on-premise/off-premise 
drinks price ratio, the prevalence of 
current drinkers and of heavy drinkers 
on the percentage of pre-drinkers. 
National Drugs Library
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Conclusion: Pre-drinking appears 
to be a worldwide phenomenon. 
The significant effects of all three 
indicators demonstrate the role 
of country-level determinants 
underpinning the prevalence of 
pre-drinking across countries. Policy 
makers could use the reported findings 
for initiating campaigns to reduce pre-
drinking behaviour.
Cross-cultural comparisons of 
drinking motives in 10 countries:  
data from the DRINC project 
Mackinnon SP, Couture ME,  
Cooper ML, Kuntsche E, O'Connor  
RM and Stewart SH (2017) Drug and 
Alcohol Review, Early online  
http://www.drugsandalcohol.ie/27108/ 
This study tested the measurement 
invariance of the Drinking Motives 
Questionnaire-Revised Short Form 
(DMQ-R-SF) in undergraduates across 
10 countries. 
Conclusion: There was broad cross-
cultural consistency in the factor 
structure and mean patterns of 
drinking motives. Undergraduate 
students appear to drink mainly 
for positive reinforcement (i.e. for 
social and enhancement reasons), 
although this tendency is particularly 
pronounced among those from more 
individualistic countries. 
‘APAAN in the neck’ — a reflection on 
some novel impurities found in seized 
materials containing amphetamine in 
Ireland during routine forensic analysis 
Power JD, Kavanagh P, McLaughlin 
G, Barry M, Dowling G and Brandt SD 
(2017) Drug Testing and Analysis,  
Early online 
http://www.drugsandalcohol.ie/27080/ 
The Republic of Ireland has a 
population of approximately 4.7 million 
citizens. Illicit drug misuse is tackled 
by legislative control mechanisms and 
the sole national forensic laboratory 
(Forensic Science Ireland) is tasked 
with detailing any controlled drugs 
present in seized materials by issuing a 
‘certificate of analysis’ which is utilized 
for court purposes.
This paper reports on the newly 
identified impurities detected in Irish 
amphetamine importation seizures, 
some of which have been published 
previously, others presented for the 
first time. Reagent purity and synthesis 
conditions have been shown to affect 
the components observed during 
analysis of seizures. Post synthesis 
additions (adulteration) and storage 
conditions may also have a profound 
effect on the analytical profiles 
obtained from seized items. The finding 
of new impurities, their abundances, 
the use of reagents that contain or 
form known existing impurities and 
post synthesis additions all have the 
potential to adversely affect existing 
profiling methodologies, which aim to 
link different seizures to a source.
Lifetime risk of mortality due 
to different levels of alcohol 
consumption in seven European 
countries: implications for low-risk 
drinking guidelines 
Shield KD, Gmel G, Gmel Gd,  
Makela P, Probst C, Room R and  
Rehm J (2017) Addiction, Early online 
http://www.drugsandalcohol.ie/27053/ 
The aim of this study was to estimate 
alcohol mortality risks for seven 
European countries based on different 
average daily alcohol consumption 
amounts.
Conclusion: If low-risk alcohol 
guidelines were based on an 
acceptable risk of 1 in 1,000 premature 
deaths, then maximums for Europe 
should be 8-10 g/day for women and 
15-20 g/day for men, and some of the 
current European guidelines would 
require downward revision.
Experiences of codeine use, misuse 
and dependence: application of Liese 
and Franz’s cognitive developmental 
model of substance abuse 
Van Hout MC, Norman I, Rich E and 
Bergin M (2017) Behavioural and 
Cognitive Psychotherapy, Early online  
http://www.drugsandalcohol.ie/26839/ 
Aims: We present the application 
of Liese and Franz’s (1996) cognitive 
developmental model of substance 
abuse to the trajectory from legitimate 
codeine use for pain, towards that 
of therapeutic and other forms of 
misuse, and physical and psychological 
dependence. It illustrates a cognitive 
behavioural analysis of the experiences 
of codeine misusers — which ‘surfaces’ 
the specific beliefs, thoughts, emotions 
and behaviours of this group of hidden 
codeine dependent individuals, who 
are distinct and unique from other 
opioid-dependent cohorts.
Conclusion: The concept mapping 
of codeine misuse and dependence 
presented here could provide 
psychological therapists working with 
individuals experiencing problems 
with codeine, misusing codeine and 
those with iatrogenic dependence, 
with an enhanced understanding of the 
key concepts involved in misuse and 
recovery pathways.
Use of prescription medication by 
individuals who died by suicide in 
Northern Ireland 
Benson T, Corry C, O’Neill S,  
Murphy S and Bunting B (2017) Archives 
of Suicide Research, Early online 
http://www.drugsandalcohol.ie/26779/ 
Aim: To understand medication use 
prior to suicide in relation to patterns, 
polypharmacy and adherence.
Conclusion: Both medication use but 
also non-adherence rates were high 
in this sample of individuals who died 
by suicide. Potential implications 
and areas for future research are 
discussed.
New psychoactive substances:  
current health-related practices  
and challenges in responding to use 
and harms in Europe
Pirona A, Bo A, Hedrich D,  
Ferri M, van Gelder N, Giraudon I, 
Montanari L, Simon R and  
Mounteney J (2017) International 
Journal on Drug Policy, 40: 84-92. 
http://www.drugsandalcohol.ie/27032/ 
The aim of this study was to explore 
current health responses to NPS, 
and highlight key issues in order to 
inform planning and implementation of 
adequate responses.
Conclusion: Immediate investments 
are required in expanding substance 
identification capabilities, competence 
building among professionals and 
dissemination of risk information 
among relevant stakeholders. The 
risks of neglecting under-served risk 
populations and failure to address 
the information needs of health 
professionals and users on NPS 
harms in a context of rapid changing 
drug markets in Europe may have 
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Hospital readmissions — independent 
predictors of 30-day readmissions 
derived from a 10 year database 
Kidney R, Sexton E, van Galen L,  
Silke B, Nanayakkara P and Kellett J 
(2017) Acute Medicine, 16(1): 4-9.  
http://www.drugsandalcohol.ie/27176/
The aim of this study was to investigate 
what factors were most strongly 
associated with early readmission. 
Conclusion: Disease and patient-
related factors beyond control of the 
hospital are the factors most strongly 
associated with 30 day readmission to 
hospital, suggesting that this may not 
be an appropriate quality indicator.
RESPoNSES
Promoting college students to seek 
help for mental health difficulties:  
a social normative approach 
Murphy D and Hennessy E (2017) 
International Journal of Mental  
Health Promotion, Early online 
http://www.drugsandalcohol.ie/26845/ 
The aim of this study was to test 
whether an online social normative 
intervention would promote college 
students’ help seeking attitudes and 
intentions. 
Conclusion: The findings of this 
study are discussed with respect to 
methodological considerations, and 
recommendations for practice and 
future research are provided for 
student counselling clinics.
Development and implementation  
of a ‘Mental Health Finder’ software 
tool within an electronic medical 
record system 
Swan D, Hannigan A, Higgins S, 
McDonnell R, Meagher D and  
Cullen W (2017) Irish Journal of  
Medical Science, 186(1): 191–200. 
http://www.drugsandalcohol.ie/27144/ 
We describe the development and 
initial implementation of a software 
tool (‘mental health finder’) within a 
widely used primary care electronic 
medical record system (EMR) in Ireland 
to enable large-scale data collection 
on the epidemiology and management 
of mental health and substance use 
problems among patients attending 
general practice.
Conclusion: The finder is a feasible 
and promising methodology for large-
scale data collection on mental health 
problems in primary care.
